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The pathway representing methionine integration and excision is an increasingly important 
target in drug design.  Methionine aminopeptidase (MetAP), a metalloprotease responsible for 
cleaving the N-terminal methionine from nascent peptides, has been the object of many studies 
aimed to produce potential anti-bacterial, anti-fungal and anti-angiogenic agents.  Though clinical 
trials are underway for several of these compounds, like fumagillin and CKD-731, they are still 
flawed based on their relatively weak inhibition and their physiological side effects.  Therefore, the 
search for novel and potent inhibitors continues.  Previous work has utilized phosphinic and 
phosphonic acid derivatives of methionine in co-crystallization studies with Escherichia coli MetAP 
(eMetAP).  The aim of the research presented in this work is to study and assay various 
phosphorus- and sulfur-containing compounds as inhibitors and substrates in an effort to learn 
more about the biochemical machinery underlying MetAP catalysis.  As well, we outline a 
predictive molecular modeling approach to MetAP inhibitor design to assist in identifying lead 
candidates amongst a body of possible molecular inhibitors.  Ultimately, we not only hope to have 
identified key functional properties of molecules potentially useful as MetAP inhibitors, but also to 
have contributed to the knowledge base of the mechanistic features involved in this enzyme’s 
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Chapter 1: Introduction 
 
 The landmark discovery of the antiobiotic penicillin has classically been regarded 
as one of the high points of the modern scientific era.  However, in recent times, this 
discovery’s clinical importance has become threatened with the ever increasing 
frequency of clinically observed drug resistance (1 - 5).  Therefore, researchers are 
extensively laboring to develop new antibiotics, and with this, are looking for novel 
targets that will surmount the means of resistance developed by Gram-negative and 
Gram-positive bacteria against current anti-bacterial agents (6).  One such line of 
inquiry has focused on enzymes comprising the biochemical machinery responsible for 
cellular protein biosynthesis.  Specifically, over the last 20 years, the enzymes 
responsible for the incorporation and removal of the N-terminal methionine in protein 
biosynthesis have become increasingly important targets. 















Figure 1. The pathway involving different steps and enzymes in methionine integration 
and excision into and from proteins.  See text for abbreviations. 
<Adapted from reference (6)> 
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The following is a brief description of the steps of the pathway: 
 
(1) Methionyl-tRNA Synthetase (MetRS) catalyzes two reactions; first, the activation of 
methionine by condensing it with adenosine triphosphate (ATP) to form an 
aminoacyladenylate Met-AMP with concomitant release of pyrophosphate (PPi); then, 
the activated Met is transferred to either tRNAf
Met (initiator) or tRNAm
Met (elongator) 
through the creation of an ester bond to the 2’-hydroxyl group of the terminal adenosine 
of tRNAMet [Scheme 1] (6, 7);  
 








 (2) In bacteria and in mitochondria, Methionyl-tRNA transformylase (MTF) then 
catalyzes the formylation reaction of the methionine that is esterified to the initiator 




) [Scheme 2] (6). 
Met-tRNAf
Met
 + fTHF fMet-tRNAf
Met




(3) At this point, protein biosynthesis occurs, utilizing fMettRNAf 
Met (in bacteria) or Met-
tRNAi
Met and Met-tRNAe





(4) Peptide deformylase (PDF) removes the N-terminal formyl group from various 
nascent proteins that contain N-formylmethionine [Scheme 3] (8).  
N-formyl-Met-peptide + H2O formate + N-Met-peptide 
Scheme 3 
 
 (5) At this point, Methionine Aminopeptidase (MetAP) becomes involved and, assuming 
PDF has acted upon the protein in the previous step, removes the now non-formylated 
N-terminal methionine in some proteins [Scheme 4] (6, 9, 10). 
N-Met-peptide + H2O Met + N-peptide 
Scheme 4 
 
MetAP is of particular interest because its activity as an intracellular enzyme, co-
translationally cleaving off the N-terminal methionine from nascent peptide chains, is 
integral to various biological processes (11, 12, 13).  Its primary function in the cell, 
referred to in the literature as N-terminal methionine excision (NME), is thought to be 
the primary means of generating N-terminal amino acid diversity, as a consequence of 
revealing the various residues in the next position after methionine, with 80% of proteins 
undergoing this type of modification in E. coli (12, 13).  Accordingly, MetAP is found 
wherever protein biosynthesis occurs, namely in the cytoplasm, mitochondria and 
plastids (11).  MetAP is part of a larger family of enzymes called the “Pita Bread Fold” 
enzymes, a unique group of metalloproteases that contain a distinctive topology 
proposed to be responsible for their substrate specificity towards N-terminal peptide 
bonds (14).  Amino-terminus removal (hence the name ‘amino – peptidase’, a type of N-
terminal exopeptidase) of methionine is believed to be required for proper protein 
functioning, subcellular localization and future degradation (12, 14).   
 4 
1.1. Structural Features 
 MetAP is divided into two classes: Type I, found in eubacteria, and Type II, which 
is found in both humans and archaea along with Type I (6, 12, 14, 15).  X-ray 
crystallography has allowed a significant amount of structural information to be obtained 
on the various types of MetAP.  For example, despite the fact that MetAP I and II exhibit 
low sequence homology, a similar protein fold is exhibited by both enzymes (14, 15).  
The ‘pita bread fold’, the namesake of MetAP’s family and found in MetAP enzymes, 
has pseudo-twofold symmetry between the N- and C- termini, each of which contains 
two alpha-helices and two antiparallel beta-sheets [Figure 2] (14, 15).  The active sites 
of both Type I and Type II are found near the core of a central beta-sheet (16).  The 
primary difference between them is a 12 kDa peptide insertion 60 residues in length that 
forms a large helical domain in the C-terminal region of the Type II form (12, 14).  The 
other major difference is the finding that eukaryotic Type I MetAP enzymes contain two 
distinct zinc finger motifs, which is in contrast to the Type II form which possesses a 
highly charged amino-terminus comprised of alternating polybasic and polyacidic 
residues (16, 17).   
 
Figure 2. Three-dimensional structure of Escherichia coli MetAP revealing ‘Pita Bread 
Fold’ symmetry.  The α-helices are numbered from N to C terminus [PDB code: 2MAT] 
<Adapted from reference (12)> 
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1.2. Active Site 
The active site of MetAP is contained within the pseudo fold (12).  Both the N- 
and C-terminal domains contribute conserved residues to form the dinuclear metal 
centre here as well, where the metal ions are coordinated by either two monodentate 
ligands, namely His-171 and Glu-204 (Escherichia coli MetAP (eMetAP) numbering) 
and by three bidentate ligands Asp-97, Asp-108 and Glu-235 (16, 18). As well, 
crystallography has shown that various solvent molecules are present in this area, 
including a metal-bridging hydroxide ion or water molecule which is believed to act as a 
nucleophile (to be discussed later) (12, 19).  The binding pockets where the substrate is 
found during catalysis are also located in and around the active site.  The S
1 
subsite 
(where the P1 residue of an inhibitor or substrate binds) is based on residues primarily 
from the N-terminal domain, despite the apparent pseudo two-fold symmetry exhibited 
by MetAP (nomenclature as defined by Schechter and Berger) [Figure 3] (19, 20).  More 
specifically,  
 
Figure 3. Schematic representation of an octapeptide in contact with an enzyme.  The 
arrow indicates the site of cleavage.  Note the numbering of the substrate and enzyme 
residues. <Adapted from reference (20)>  
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this region is relatively hydrophobic, and consists of amino acid residues His-79, Cys-
59, Cys-70, Tyr-62, Tyr-65, Phe-177 and Trp-221 [Figure 4] (19).   However, the P1’ 
residue of the substrate binds in the S
1
’ subsite, and appears to be a shallow pocket 
comprised of the residues Glu-204, Gln-233, Met-206 and Tyr-168 [Figure 4] (19).  
 
Figure 4. Active site of MetAP with important residues displayed [PDB code: 2MAT] 
<Adapted from reference (20)> 
Based on previous studies, His 79 is clearly an important amino acid in the active 
site of MetAP (6).  However, its precise role has been debated, as besides its function 
during catalysis already mentioned, others propose that His 79 may form a hydrogen 
bond with the leaving scissile nitrogen atom of the peptide bond being hydrolyzed (19).  
Due to the funnel-like nature of the active site, such a bond may be required as the wide 
mouth at the opening of the active site soon becomes quite narrow deep within the 
cavity itself (6).  It has been noted that the binding of phosphorus-based analogues of 
 7 
methionine to eMetAP fosters hydrogen bond formation during catalysis at His79 (14).  
Further evidence from the structurally equivalent histidine residue in human MetAP 
(hMetAP) in complex with fumagillin, an epoxide-containing natural product, and several 








Figure 5. The anti-angiogenic compound, fumagilin. 
 
  Other residues in the active site of MetAP are important for catalysis.  One such 
example is Asp-97 – its mutation to alanine, glutamate or asparagine effectively 
removes the dinuclear metal center of MetAP, based on the disruption of the metal-
coordination required in the active site where Asp-97 plays a large role (21).  
Consequently, compared to wild-type enzyme, there is a vast reduction in enzymatic 
activity (21).  On the other hand, altering certain residues in the active site modifies 
activity rather than eliminates it.  This is seen in the case of His-63 which, when mutated 
to alanine, significantly diminishes the ability of MetAP to act upon small peptidic 
substrates.  However, MetAP’s ability to cleave the N-terminal Met of large peptides is 
largely unaffected, and at times, seems enhanced (22).  It is believed that the loss of 
His-63 changes the orientation of regional residues and as a point of interest, additional 
hydrophobic and hydrophilic bonding interactions are created fostering a greater ability 
to process substrate (22). 
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1.3. Metal Co-Factors 
The dimetal center is a distinguishing feature of MetAP enzymes [Figure 6].  The 
initial finding that treatment with ethylenediaminetetraacetic acis (EDTA) renders MetAP 
inactive uncovered the metal-dependent nature of MetAP (6).  The dinuclear metal 
center in E. coli MetAP (eMetAP) is formed by the contribution of conserved residues 
from the N- and C- terminal domains (monodentate ligands, such as His-171 or 
bidentate ligands, such as Asp-97, Asp-108, Glu-235 ) [Figure 4].  A metal-bridging 
water or hydroxide ion is thought to act as the nucleophile during catalysis (19). Though 
Co2+ is historically thought to be the most common type of metal to be found in this 
region, Zn2+, Mn2+, and Ni2+ have also been documented to populate this region (6, 10, 
12, 20, 22, 23).  In addition, though Mn2+ and Co2+ maintain optimum enzymatic activity, 
changing the type of metal found in the dinuclear center does not eliminate activity, and 
in the case of yeast MetAP I (yMetAP I), Zn2+ actually enhances catalytic efficacy when 
substituted for Co2+ (20).  
 
Figure 6.  Three-dimensional representation of the dinuclear center of MetAP showing a 
phosphonate analogue of methionine bound in the active site.  In dark blue are the metal 
ions [PDB code: ICS3] <Adapted from reference (23)> 
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 This idea of metal selectivity is also quite pronounced in the search for efficient 
MetAP inhibitors.  Several journal articles have been published that demonstrate 
specific types of inhibitors may be selective for different metalloforms of MetAP (24, 25, 
26).  For example, catechol inhibitors of MetAP containing 5- and 6-membered ring 
groups have been shown to inhibit MetAP much more potently in the presence of Fe(II) 
than other divalent metal ions commonly utilized in in vitro MetAP catalysis (25).   This 
same theme permeates many different types of inhibitors (for example, Mn(II) as the 
metal of choice – see Figure 7), and its further elucidation provides insight not only into 
the active site of MetAP, but exactly what kind of metal selectivity, and under what 
conditions catalysis is optimal for this critical enzyme.    
 
Figure 7. Stereoviews of eMetAP with a Mn(II)-selective inhibitor, demonstrating the 
Mn(II) coordination in the active site <Taken from reference (26)> 
 
Interestingly, it has been noted that the presence of a single metal atom can 
allow MetAP to function fully (27).  The proposed role of the second metal ion in 
catalysis is to bind and position the terminal amino group of the polypeptide chain.  
However, D’Souza and colleagues have posited that this role can in fact be carried out 
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by active-site amino acid groups Asp-97, Asp-108, and Glu-235, which form a negative 
pocket in the appropriate position to bind the N-terminal amine moiety (31).  Therefore, 
they have suggested that the binding of the second metal ion may have no catalytic role 
but may play a regulatory one (31). 
1.4. Physiological Role 
The removal of the N-terminal methionine is a crucial stage in protein maturation 
(32).  In fact, some proteins fail to function until this happens (12).  However, this seems 
to occur only if the penultimate residue is small and uncharged, typically serine, 
threonine, valine, proline, glycine, alanine and cysteine, ultimately a function of the P1’ 
residue’s radius of gyration [Figure 8] (6, 12, 14).  It appears that these residues 
influence whether the initiator methionine is cleaved, controlling MetAP specificity (6).  
Incidentally, this substrate preference is antithetical to the ‘N-end rule’ for protein 
degradation, and MetAP will fail to cleave the N-amide bond should a ‘destabilizing’ 
residue be present (23). 
 
Figure 8.  A representation of the radius of gyration of an amino acid side chain.  The 
clouded region indicates the space occupied by the mobility of R1 on account of bond 
rotation. 
 
MetAP’s importance biologically is underscored by the lethality of deleting or 
inhibiting MetAP genes or gene products in Saccharomyces cerevisiae, Salmonella 
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typhimurium and E. coli (32, 33, 34).  More specifically, it has been shown that the N-
terminal domain extensions of some MetAPs may be important for targeting the enzyme 
to the ribosome or other cellular partners via protein–protein, protein–DNA or protein–
RNA interactions (14). For instance, a slow-growth phenotype has been observed for 
the point and deletion mutants of the zinc finger domains of yMetAP (35).      
 
Accompanying this is the quite fascinating speculation that the N-terminal domain 
of the p67 protein, an hMetAP homolog, seems to promote protein synthesis by 
phosphorylating the α-subunit of translation initiation factor eIF2, thereby protecting it 
(36, 37, 38).  At the level of the organism, such as Drosophillia, this results in eye and 
wing vein defects and an aberrant distribution of MetAP II mRNA over the course of 
development, suggesting a mechanism whereby MetAP exerts control at the 
translational level, or possibly during post-translational processing (39).   MetAP is also 
believed to be involved in the process of angiogenesis (6, 12, 14).  A very interesting 
study done by one of the unfortunately now deceased pioneers of the angiogenesis 
field, Judah Folkman, showed how knocking out MetAP2 in transgenic murine models 
through targeted gene disrupted leads to gastrulic defects and ultimately, necrotic 
defects in mouse embryos (40).  As a result, MetAP is an attractive target 
pharmacologically because of its inactivation by anti-angiogenesis agents, fumagillin 
and its synthetic analogue, TNP-470, and these have thus far proven effective in clinical 





Figure 9. The natural product Fumagillin and its derivative, TNP-470. 
 
1.5. Substrate Specificity 
 Though eukaryotic organisms express two types of MetAP (MetAP I and MetAP 
II), they both exhibit similar substrate specificities (14).  However, subtle differences 
exist in their substrate preference, demarcated by the efficiency with which they perform 
N-terminal methionine excision (NME), and in their inhibition by fumagillin.  For 
example, the yeast MetAP I (yMetAP I) is unable to cleave certain substrates that 
yMetAP II can process, but is selectively inhibited by fumagillin over type I (15).  In 
addition, though both MetAP I and MetAP II exhibit discrete substrate preferences, 
siRNA studies have shown that depletion of either enzyme causes human cell growth 
impediment (41).   
As mentioned already, MetAP will only remove the N-terminal Met (P1) when the 
second residue (P1’) is small and uncharged (ex. Gly, Ala, Ser, Thr, Val, Pro, Cys) and 
the peptide is at least three residues in length (10, 42).  This seems to contradict the 
widely accepted ‘N-end rule’ for protein life span and degradation, where the lifetime of 
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a protein is determined by the identity of its N-terminal residue (43).  On the contrary, 
MetAP will not function if the amino acid in the penultimate position of the substrate is 
considered ‘destabilizing’ (12).   However, there are exceptions.  This stochastic rule 
emerged out of early bioinformatics analysis based on a compilation of available protein 
sequences of the time (which were few), and was confirmed with only about a dozen 
model tri- and tetrapeptides (11).  The authors of these studies suggested that the 
process was statistical rather than stochastic and that cleavage efficiency was 
correlated with side-chain length or gyration radius solely at P1’ (11, 44).  However, 
recent evidence has emerged that suggests residues in positions P1’, P2’, P3’ and even 
P4’ also contribute to cleavage efficiency and affect cleavage probability, and it is not 
simply the nature of the penultimate position that solely determines selectivity [Figure 
10] (11).   
 
Figure 10.  The speed of excision by MetAP depending on the penultimate residue with 
various substitutions in that position <Taken from reference (45)> 
Interestingly, despite NME being a rapid and efficient process, the N-terminal 
methionine residue may erroneously be retained on some proteins that are 
recombinantly overproduced in E. coli (45).  This has been especially true when strong 
promoters like T7 or T5 are used (45). This phenomenon is most probably due to the 
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saturation of the peptide deformylase and MetAP capacities or targeting of the nascent 
protein, for example, into inclusion bodies (45). 
 
1.6. Catalytic Mechanism 
 
In spite of the dimetal centre that has been detected by X-ray crystallography 
within the active sites of various MetAP, and also bearing in mind that previous 
mechanisms proposed for MetAP make use of two metal ions, it is believed that MetAP 
requires only one metal ion to function, and therefore is based on a mono-metalated 
mechanism.   
 
 
Mechanism [Scheme 5]:  
Initially, there is nucleophilic attack by one of the active site water molecules on 
the N-terminus of the substrate.  This is followed by a proton transfer from the µ-
hydroxide to the carbonyl group of the substrate, and a subsequent proton abstraction 
from His-73.  As well, Glutamate-204 abstracts the remaining proton of the carbonyl 
group of the substrate, all leading to a tetrahedral intermediate of the substrate.  His-
178 may facilitate the collapse of this intermediate, since it could act as a proton donor 
to the departing amino nitrogen.  His-79 functions to orient the substrate for catalysis 















































































































Scheme 5. The proposed catalytic mechanism of eMetAP. One should note that the water 
molecule ligated to the metal center may be present as a hydroxide. <Adapted from 
reference (19)> 
 
1.7. Inhibitors of MetAP 
 To date, many synthetic compounds have been proposed to act as inhibitors of 
MetAP and demonstrate possible therapeutic value.  These compounds include those 
containing keto heterocycles, aminoketones, alpha-hydroxy-beta-amino acids, triazoles, 
hydroxyamides, benzamides and sulfonamides, and each class has various benefits 
and drawbacks (46 - 51).  For instance, Sheppard and colleagues designed and tested 
a very promising set of anthranilic acid sulfonamides, which in vitro inhibited MetAP II 
fairly strongly with an IC50 of 2.4 µM (50). However, the addition of human serum 
albumin (HSA) significantly diminished inhibition, presumably because of extensive 
binding of the inhibitor to HSA (99.7-99.8 % protein bound in rat plasma) (50).   
Both Type I and Type II MetAP enzymes have been shown to be possible targets 
of several anti-fungal, anti-microbial and anti-angiogenic agents (6).  However, 
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excitement surrounding MetAP inhibition truly began when it was found to be the 
specific target of the epoxide-containing anti-tumor natural product fumagillin (49).  Its 
mode of action through irreversible covalent modification of MetAP resulted in a 
decrease of endothelial cell growth (52).  These findings were soon followed by 
experimental results that implied these compounds impeded angiogenesis (53).  
Another compound dubbed ‘TNP-470’, a synthetic analogue of fumagillin, shows even 
higher efficacy in the therapy of specific types of cancer and is currently in clinical trials 
(54, 55).  However, these compounds are still relatively weak inhibitors of MetAP and 
elicit deleterious side effects.  Fumagillin, for example, has been observed to lead to 
severe weight loss with long-term administration (6).  Therefore, the search for other 
inhibitors has continued.  With this, many other types of compounds have been 
designed and tested against MetAP in the hopes of having strong inhibitory effects on 
MetAP. 
Angiogenesis is the process by which blood vessels form and grow.  During 
tumour metastasis, nutrients and oxygen are needed to sustain newly formed tumours 
and to enable their growth at new sites distal from the original site of tumor formation 
(6).  Agents which specifically combat the formation of new blood vessels also decrease 
the formation of new metastatic tumors (6).  As mentioned previously, MetAP is 
specifically inhibited by fumagillin and its synthetic analogues, such as TNP-470 and 
CKD-731, and results in decreased angiogenesis and endothelial cell growth upon their 
administration (6).  As a point of interest, CKD-731 is seen to act against endothelial cell 
growth 1000 times more potently than fumagillin and it is thought this same affinity may 
also hold true in studies aimed at MetAP inhibition (56).   
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1.8. In Silico Medicinal Chemistry and Molecular Modeling 
Medicinal chemistry has been around since the time of ancient Egypt (57).  Their 
primitive but often innovative methods by which medicines were discovered has 
changed quite considerably since that era.  In the 1960’s, it became much more clear 
that a unique relationship existed between the structure of a chemical entity to be used 
medicinally, and the biological activity it induced (58).  Since then, various strategies 
have been developed in order to discover therapeutic agents.  Yet, few have seen as 
many of the technological advances in the past 20 years as computer-aided drug design 
and molecular modeling.  In fact, by today’s standards, it is almost inconceivable for the 
drug discovery process to even take place without the use of computational 
methodologies at some point during lines of inquiry in to therapeutics (59).  Combining 
the knowledge and technology of computational chemistry, bioinformatics, conventional 
medicinal chemistry, biochemistry, and structural biology and chemistry, the successful 
application of computer-aided drug design and molecular modeling to medicinal 
chemistry has been a key approach to the design of medicinal agents.  Moreover, the 
improved structural capabilities (highly efficient protein generation and purification 
techniques, high throughput crystallography, structure-activity relationship studies 
through advanced NMR methods, etc.), enhanced computational algorithms 
simultaneously with increasingly powerful and affordable computing power, along with 
the well developed high-throughput chemistry available (e.g. parallel synthesis, specific 
library design, etc.) have changed the face of contemporary medicinal chemistry and 
has undoubtedly contributed to the many successes involved thus far in the field (59). 
 18 
 In the last 20 years, the frequency with which molecular modeling studies have 
been incorporated into drug discovery-related publications has increased spectacularly 
[Figure 11].  For example, in 1999, 82 publications were available that looked at drug 
design using molecular modeling.  A comparison of that figure to 10 years before, in 
1989, shows that only 14 drug-design papers made use of molecular modeling.  
However, at the time of writing, half way through 2009, 1402 papers were published that 
specifically integrated molecular modeling into their drug design research.  This most 
dramatic shift toward the use of computational methods in drug design is undeniable, 
and molecular modeling has clearly become an essential tool in the drug discovery 
process.  
Molecular Modeling in Drug Design 


























Figure 11.  The number of publications in drug-design that use molecular modeling in 
1989, 1999, and Mid-2009 searched on PubMed using the search terms “inhibitor” and 
“molecular modeling” as of August, 2009. 
 
 There has been very little work to date that studies methionine aminopeptidase 
using molecular modeling.  That which does exist employs either a molecular 
mechanics view of MetAP (2 papers – discussed later), or uses molecular modeling in 
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the inhibitor design process (3 papers – discussed later).  Considering the importance of 
MetAP as a potent anti-cancer target, and the number of publications that mention this 
while also focusing on MetAP inhibitor design, as well as the success seen using in 
silico methods in other areas of inhibitor design research like NNRTIs against HIV, it is 
quite surprising that more reports have not been published with MetAP [Figure 12].  
Perhaps this will change if methionine aminopeptidase’s importance in tumorgenesis 
becomes more widely known and accepted.       
 
Figure 12.  CKD-731, a potent analogue of fumagilin, docked in silico with eMet-AP2 
<Taken from reference (60)> 
 
 
1.9. Statement of Goal 
 
 There is great therapeutic value in understanding MetAP catalysis.  Our aims 
with this research centre on probing the Escherichia coli MetAP through various means 
in order to get a better understanding of the enzyme's catalytic mechanism, active site, 
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substrate specificity, metal preferences, and inhibition.  By using a fluorescence-based 
biochemical assay that will monitor enzyme activity, we hope to be able to assess the 
interactions that may exist between MetAP and various compounds possessing unique 
functional groups.  We also intend to perform various types of molecular modeling in an 
effort to provide further insight into how to focus the drug design process in MetAP 
inhibitory studies, while also giving an idea of how the compounds we use to probe 
MetAP perform in this context comparatively to the assays we will perform.  Taken 
together, pursuing these lines of inquiry will allow us to acquire a firmer grasp on MetAP 
and contribute to the knowledge that may one day lead to effective preventative 






















Chapter 2: Probing Methionine Aminopeptidase 
2.1. Introduction 
As touched upon in the introduction, MetAP has become a very important 
therapeutic target (6).  Its involvement in the removal of nascent peptide N-terminal 
methionine residues is a vital component in the biosynthetic pathway, lethality resulting 
in its absence and functionally relevant in various pathologies (6, 32, 40).  Many 
different kinds of compounds have been proposed to act as inhibitors of MetAP, with 
various functional components meant to enhance inhibitory potency utilized (46 - 51).  
We are interested in studying those that resemble natural substrates of MetAP, as well 
as compounds resembling enzyme reaction intermediates, as their assessment may 
also impart knowledge on the catalytic mechanism and active site of MetAP in addition 
to possibly diminishing enzymatic activity.   
 
2.1.1. Transition-State Analogues  
The transition state of a chemical reaction is a particular configuration along a 
reaction coordinate which corresponds to the highest energy of a reaction intermelong 
the reaction pathway [Figure 13].  Conceptually, it is a chemical reaction or process that 
involves the rearrangement of matter as proceeding through a continuous change or 
"transition state" in the relative positions and potential energies of the constituent atoms 
and molecules (61).  Designing enzyme inhibitors as structural analogues of reaction 
intermediates, and as apparent analogues of transition states, is well established.  This 
paradigm is based on replacing the main substrate functional group so as to entirely 
alter the reacting system, for example, substitution of a scissile bond by a non-scissile 
one. This allows the integration of features into a stable molecule that mimic primary 
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transition–state interactions of the natural substrate and the enzyme active site (62).  
Therefore, this approach aims to exploit the capability of an enzyme active site to 
stabilize a transition state structure so that the stable transition state analogue is bound 
with a far higher affinity than the normal substrate (63). 
 
Figure 13. The transition state energy diagram; G = Gibb’s free energy, A + B = reactants, 
P + Q = products, X‡ = transition state.  Note the difference in reaction energy between 
the ∆Greaction and ∆G
‡. <Adapted from reference (61)> 
 
Methionine phosphinate and phosphonates have been shown to bind to the 
active site of eMetAP (46).  Phosphorus-containing compounds form a third hydrogen 
bond between an oxygen atom of the phosphonate group and His 79, which is either 
manifest of movement or charge neutralization and is indicative of His 79 directly 
interacting with the amide nitrogen of the scissile peptide bond.  The significance of 
such a finding is the similarity between the phosphonates / phosphinates and the 
natural MetAP substrate transition state (46).  To a similar extent, it is noteworthy that 
mutations in the aforementioned active site residue His 79 inactivate the enzyme (46, 
54). 
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Inquiry into phosphorous analogues of alpha-amino acids like methionine began 
in the 1940’s, but underwent a renaissance during the late 1970’s and early 1980’s 
because of their observed anti-bacterial activity, potently inhibiting bacterial cell wall 
biosynthesis (64).  More recently, their anti-angiogenic capabilities have been 
investigated and have resulted in further design and testing of compounds with this aim 
(64). The tetrahedral intermediate for the hydrolysis of the N-terminal methionine of a 

















Figure 14. Top panel: The tetrahedral intermediate formed when OH attacks 
CH3(O)NHCH3 as a nucleophile (left), phosphonic acid, which resembles a tetrahedral 
intermediate (right). Bottom panel: The electrostatic potential of the tetrahedral 
intermediate (left) and phosphonic (right) acid mapped on to the electron density at the 
RHF/6-31+G* level. 
 
It would therefore be of interest to evaluate the racemic form of amino acid phosphonate 
analogues with E. coli MAP to ascertain precisely what level of inhibition can be 
obtained with these simpler analogues.  Although chiral analogues can also be 
prepared, the racemic mixture would allow for a more crude, preliminary analysis of 
these types of compounds, unmodified at this stage by conjugation with additional 
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groups on the phosphorus.  In collaboration with our laboratory, Professor B. Matthews 
and his group (University of Oregon) have determined the molecular structure of MetAP 
bound with the phosphonate analogues of methionine (46).  Therefore, it is of interest to 
build upon this previous work and continue to look into amino acid phosphonate 
analogues and their inhibitory potential. 
 
2.1.2. Substrate-Mimic Inhibitors  
Designing inhibitors that resemble an enzyme’s natural substrate is a strategy 
that has been long employed in drug design with great success.  One such example in 
the case of MetAP has been to model novel drugs based on the structure of the natural 
product bestatin [Figure 15] (46).  By replacing the N-terminal side chain of bestatin with 
that of norleucine and by putting an alanine at the P1′ position, a non-hydrolyzable 
substrate analogue (AHHpA-Ala-Leu-Val-Phe-OMe) was produced which inhibited 
eMetAP.  An inhibitory concentration (50%, IC50) was determined to be 5 uM (19).  X-
Ray crystallography has shown the binding mode of the modified inhibitor in complex 
with the active site of eMetAP [Figure 16] (19).  A number of solvent atoms are seen to 
be displaced relative to the metal center, with the coordination number of the first cobalt 
(Co1) changing from five to six.  The inhibitor interacts with the enzyme in three ways: 
ligation to Co1 via the keto oxygen of the pseudo-peptide linkage of the AHHpA moiety, 
N-terminal ligation to the second cobalt atom (Co2), and a bridging coordination 
between Co1 and Co2 (19).  Additionally, two hydrogen bonds are formed, specifically 













Figure 15. Bestatin, a natural product inhibitor of MetAP. 
 
 
Figure 16. The bestatin-based inhibitor MetAP inhibitor containing (3R)-amino-(2S)-
hydroxyheptanoic acid (AHHpA), in complex with eMetAP’s active site. [PDB code: 
3MAT] <Taken from reference (19)> 
 
Lowther et al.’s findings are intriguing, and encourage exploring novel non-hydrolyzable 
analogues to further understand the nature of MetAP activity.  Previous work has shown 
that thiopeptides can resist the action of a protease (65).  For example, the work of 
Belleau and coworkers has shown that thiopeptides were effective in blocking 
metalloendopeptidase-mediated release of lysozymes (65).  Even more compelling is 
the fact that Fosamprenavir and Tipranavir, two commercially popular protease 
inhibitors (PIs) contain sulfonate groups, while Nelfanavir, another well-known PI 
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contains a thioester (66). As well, with our interest in compounds that have similar 
structures to the natural substrates of MetAP, the sulfur atom contained within 
methionine is a point of curiosity, as we would like to answer the question of what might 
occur with MetAP if the thiomethyl functionality of methionine was replaced by a 
fluorinated version which altered the steric and electronics of this moiety. Doing so 
would give further insight into the catalytic mechanism and active site dynamics of 
MetAP.   
 
2.2. MetAP’s Metal Identity Crisis 
 MetAP, as a metalloprotease, requires divalent metal ion co-factors in its active 
site to function.  Without metal, apo-MetAP is unable to hydrolyze the Met-AMC 
substrate.  However, as touched upon earlier, the precise identity of the metal ion 
required by the E. coli MetAP is disputed (6, 10, 12, 20, 22, 23).  Classically, Co2+ has 
been the metal most researchers believe facilitates MetAP activity (6).  However, more 
recent studies have shown that in the case of yMetAP, Zn2+ is the preferred ion (20).  In 
other reports, Fe2+ is believed to play this crucial role in eMetAP, with several other 
research groups exhibiting different metal content in the active site (25, 67, 70). 
 
 As we are interested in MetAP’s role in the protein biosynthetic pathway, we 
decided to investigate what metal serves as a co-factor for the enzyme using the 
fluorogenic assay with Met-AMC using various divalent metal ions to confirm previous 
reports before we undertook a study of various compounds as potential inhibitors.         
 
 27 
2.2.1. Met-AMC Fluorogenic Assay 
 Much of the work done in our laboratory on MetAP catalysis has been done using 
a high performance liquid chromatography-based assay to assess Met cleavage (67), 
as well as a coupled assay involving MetAP and prolyl iminopeptidase to measure 
enzyme kinetics (68).  The HPLC assay assesses eMetAP’s cleavage of a standard 
peptide previously utilized in our laboratory, Met-Gly-Met-Met, and whether adding 
inhibitors increases or decreases the accumulation of free N-terminal Met-truncated 
peptide (67) [Scheme 6].  
Met Gly Met Met
MetAP









 The coupled MetAP reaction couples MetAP catalysis to the enzyme prolyl 
iminopeptidase (ProAP).  A standard dipeptide substrate, methionylprolyl-p-nitroanilide 
(Met-Pro-pNA), has been used for optimization of the coupled assay as developed by 
Zhou et al. (68).  ProAP is best suited for coupling to the MetAP reaction because it has 
a different substrate specificity from MetAP while also performing catalysis at a rate 
higher than the native MetAP reaction.  Specifically, ProAP from Bacillus coagulans is 
employed because it exhibits a high specificity for N-terminal prolyl residues, which 
MetAP does not act upon, and also shows no detectable activity towards a Met-Pro-
pNA dipeptide (68), which MetAP acts upon. 
 
However, after several attempts to apply this assay approach in our laboratory, 
these methods were abandoned for several reasons.  For one, our early attempts at 
expressing ProAP proved infeasible.  The plasmid we obtained from Dr. Zhou (Ohio 
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State University, Columbus, Ohio) , the person who developed the assay, for ProAP did 
not have the correct sequence. In addition it was not possible to amplify with supplied 
DNA by PCR and it was not possible to express the correct protein.  Another reason for 
changing our approach to assaying MetAP was that the HPLC assay is very lengthy and 
laborious, and the results are often difficult to interpret based on co-purification of the 
products.  However, our primary reason for abandoning the previous assay protocols 
was because of our intent to adopt a new, simplified but powerful and fast fluorogenic 
assay, previously made use in a metal-selective inhibitor study on MetAP by Li and 
colleagues at the Chinese Academy of Sciences in Shanghai, China (69).   
 
In Li et al.’s publication, the authors describe their use of the commercially 
available substrate Met-7-amino-4-methylcoumarin (MetAMC) from Bacham Bioscience 
(King of Prussia, PA), which is assayed along with MetAP on a microplate reader 
capable of measuring fluorescence [Scheme 7].  To this, they were able to add 
inhibitors from a compound library to their assay mixture, and determine whether the 
inhibitor’s presence caused a relative decrease in fluorescence as a result of it’s 
preferred metal selectivity (69).  This inspired us to attempt to incorporate the same 












Under appropriate conditions using a fluorescence microplate reader, one is 
capable of monitoring an assay in real-time, following the reaction as it proceeds, and 
obtaining kinetic data simultaneously.  Accordingly, MetAP’s cleavage of Met-AMC 
should cause an increase in the presence of fluorescence.  The greater the cleavage, 
the greater the concurrent increase in fluorescence.  However, with compounds present 
in the assay that would be thought to inhibit MetAP, fluorescence readings would be 
less than simply the enzyme alone with the substrate.  This same train of thought would 
also apply to metal selectivity – if the metal ion present in the assay is conducive to 
MetAP activity, fluorescence readings should indicate this as a relative increase in 
enzymatic cleavage of the substrate, and likewise for a metal which does not activate 
the enzyme, no fluorescence should be observed. Appropriate background hydrolysis of 





Commercially obtained recombinant E. coli Methionine Aminopeptidase (20 ug in 
20 µL) was obtained from R&D Systems, Inc. (Minneapolis, MN) and stored at -80 oC.  
Methionine-7-amino-4-methyl coumarin (Met-AMC) fluorogenic substrate was obtained 
Bacham Bioscience (King of Prussia, PA).  Black 96-well opaque microplates were 




2.2.2.2. Met-AMC Assay 
When needed for assays, reMetAP (20 ug in 20 µL) was reconstituted in a 100 
µL buffer solution at pH 7.5 with 50 mM HEPES and 0.1 M NaCl.  Kinetic assessment of 
enzyme activity was adapted from the procedure of Li et. al. (69) with the following 
conditions. Assays were performed on a SpectraMax 340 microplate reader set on 
fluorescence detection, from Molecular Devices (Sunnyvale, CA) and controlled by 
Softmax software.  Assays with Met-AMC (Bacham Bioscience, King of Prussia, PA) 
were performed in 96-well clear black, opaque microplates.  During each assay, the 
formation of 7-amido-4-methylcoumarin (AMC) was monitored continuously for 15 to 
30 min at room temperature (25 oC) by fluorescence (λex=360 nm, λem=460 nm).  In 
each 200 µL well, an 80 µL reaction mixture was added that contained 50 mM HEPES, 
pH 7.0, 1mM NaCl, and and 0.1 uM apo-eMetAP (which translated to 0.75 µL being 
added to a well).  The concentrations of Met-AMC substrate was varied to 1mM, which 
is different from the single concentration used by Li et. al.(69).  However, unlike the 
aforementioned group, we did not vary metal concentrations, and kept them static at 0.1 
mM.  In addition to Co2+, the metal typically regarded as the preferred metal in the 
active site of MetAP, several other metal-containing buffer solutions were prepared, at 
0.1 mM concentration.  In particular, the additional metals used were: Zn2+ / Mn2+ / Mg2+ 
/ Ca2+ / Ni2+ / Fe2+.  Kinetic constants Km and kcat were obtained using the GraFit6
TM 
software through non-linear regression fitting of the rate v.s. substrate concentration 





2.2.2.3. Metal-Free Assay Conditions 
It was assumed originally that our commercially purchased recombinant eMetAP 
was completely devoid of metal content.  This was further presumed by the suppliers 
themselves, who confirmed as much when contacted directly.  However, our initial 
experiments with the enzyme quickly demonstrated that such was not the case, and in 
fact, background metal ions were present in the original enzyme stock as the levels of 
Met-AMC hydrolysis with no metal present in the buffer solution were significantly higher 
than expected (at times, almost as high as assays run with metal present!).  Therefore, 
a protocol was developed to insure that our assay was completely free of metal so that 
the results obtained with our assays would not be confounded with exogenous metal.  
This also served as a means to permit us to experiment with different, specific divalent 
metal ions in our assays, being able to assess the differential level of activation by the 
enzyme with various divalent metals in the active site as the particular metal ion 
involved in metalloprotease catalysis is hotly debated (6, 10, 12, 20, 22, 23). 
 
To put it simply, in order to remove all possible traces of exogenous metal from 
the assays, everything involved in the assay had to be treated as a possible source, and 
dealt with accordingly.  Thus, all apparatus’ and materials involved, from the plastic 
weighing trays to the micropipette tips, were soaked in 20% nitric acid solution overnight 
prior to running assays.  The enzyme itself (1 uM, 17 µL) was taken from the original 
stock solution and placed for 24 to 72 hours in 983 uL of Chelex-treated buffer (total 
volume: 1 mL) and incubated with 2,6-pyridinedicarboxylic acid (DPA) (0.2 mM, 0.033 
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g), which had been successfully utilized in our lab and in the literature to remove metals 
from other metalloenzymes [Figure 17] (70).  Before performing assays, the dialyzed 
enzyme was passed through an Ultrafree-MC centrifugal filter (30 KDa MW cut-off) and 
reconstituted in 17 µL of original buffer solution [1 uM].  All nitric acid soaked assay 
relevant supplies were rinsed in Chelex-treated MQW water.  Once these procedures  
 
Figure 17. 2,6-Pyridinedicarboxylic acid 
 
were carried out, externally-derived metal contamination had been reduced by 
approximately 80%, based on the relative fluorescence readings of assays run with the 
enzyme and substrate the presence of a non-metal containing buffer solution.  
 
2.2.2.4. Fe2+ in Assays 
E. coli MetAP is known to function optimally with Fe2+ during catalytic activity 
(71).  As mentioned previously, it has even been investigated whether certain inhibitors 
function more potently, or are “Fe2+-selective” (25).  However, the precise identity of the 
metal which MetAP, and metalloproteases utilize, is hotly contested, with much 
literature on the subject having been published in order to establish a definitive role for 
one divalent metal over another.  We decided we would like to investigate this as well, 
and utilize the fluorogenic assay to this end.  
 
Unfortunately, utilizing Fe2+ during biochemical assays is not as simple as 
dissolving the ferrous sulfate (FeSO4) metal crystals into the buffer solution.  Fe
2+, once 
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dissolved in solution, very readily and quickly oxidizes to Fe3+.  In fact, if one does not 
expect this to occur, then they are quite shocked as almost as fast as the iron is added, 
the buffer solution turns purple, and then black depending on the concentration [Figure 
18].  So, based on the necessity for Fe in its +2 oxidation state form to populate the  
 
Figure 18. In the first panel, a buffer solution is shown before FeSO4 is added.  In the 
second panel, FeSO4 has been added and moments later, rapid oxidation from Fe
2+ to 
Fe3+ has occurred. 
 
catalytic region of MetAP, appropriate steps had to be taken to ensure that rapid 
oxidation to the ferric species of Fe did not occur.   
 
Wang and colleagues (2008), in their report on inhibitors selective for the Fe(II)-
form of MetAP, document their usage of ascorbic acid when performing their assays as 
an anti-oxidant, preventing oxidation to Fe(III), with which MetAP cannot function (25).  
The anti-oxidative properties of ascorbic acid are well established (72).  Therefore, in 
order to prevent ferrous oxidation from occurring in our own assays, we developed a 
modified version of their buffer preparation procedure.  Before adding the metal, argon 
gas was bubbled in for approximately 30 minutes, with all oxygen being exited from the 
system to insure the entire environment was oxygen-free.  After 15 minutes, 0.1 mM of 
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ascorbic acid was added to the solution while argon gas was still being bubbled into the 
buffer.  We waited another 15 minutes while the solution continued to mix, and then 
carefully added 0.1 mM FeSO4, returning it to the argon atmosphere for five minutes.  
Assays were then quickly performed, as even in spite of our cautious preparation of the 
buffer and containment of it during experiments, oxidation slowly occurred.  This is 
demonstrated in Figure 19, which shows the level of relative activity of MetAP in relative 
fluorescence units (R.F.U.) over time using the prepared Fe2+ buffer.   
Figure 19. MetAP activity as a function of time, reported in R.F.U., using an Fe(II) buffer 
solution.  As time passes, MetAP activity decreases, presumably due to Fe2+ oxidation to 
Fe3+. 
 
As time elapses during assay experiments, there is a relative decrease in activity 
of eMetAP using the Fe(II) buffer prepared.  When optimizing the assay originally, at 
times, addition of FeSO4 would automatically result in a blackened solution, indicating 
rapid oxidation from Fe2+ to Fe3+.  When attempting to perform assays using this 
darkened buffer, with fresh enzyme or enzyme used before, there was virtually no 
activity present.  This then motivated us to check if in fact there was a correlation 
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between the level of oxidation having occurred in the buffer (perceptible by colour), and 
how much relative activity there was in the assays performed with this perpetually 
colour-changing solution (from clear to purple to black) [Figure 18].  So, the original 
enzyme solution made use of in the assay was assessed for activity using the assay 
procedure specified in Section 2.2.2.2., with new substrate, each hour after buffer 
preparation with this slowly oxidizing buffer.  To compare, a new batch of enzyme was 
used as a control, as we were not sure whether the enzyme was simply denatured or 
not.  The results were identical whether the original enzyme batch was used, or the 
enzyme freshly removed from -80 oC.  However, upon preparing a fresh buffer solution, 
activity was restored to optimal levels.  Interestingly, during preliminary Fe2+ assays, if 
the buffer was not disposed of at the end of running experiments, and was left 
overnight, the next day, the solution was completely black and opaque, similar to the 
appearance of the solution in the second panel of Figure 18.  
  
In addition to these concerns, there was also the issue that Fe2+, in complex with 
the ascorbic acid, might function itself as an entity capable of hydrolyzing Met-AMC.  
Clearly, this was problematic as the results from the Fe2+ experiments would have to be 
interpreted with the proper controls.  However, at the same time, despite our 
apprehensions, it was of interest to assess whether this indeed occurred, as it would 
have yielded yet another function of the almost inexhaustible roles ascorbic acid plays 
biologically, and a further demonstration of the role ascorbic acid and Fe play 
catalytically in biological systems (73, 74).  Assays run with Fe2+ and ascorbic acid did 
in fact show some Met-AMC hydrolysis, ranging from between 5 to 10% of what we 
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used as the control experiment, being the Fe2+ + MetAP assay.  This is quite minute 
however, so it was simply factored in as background signal.   
 
2.2.3. Results and Discussion  
2.2.3.1. Metal-Activation and Kinetics of MetAP with Various Divalent Metal Ions 
As can be seen from Table 1, there is quite a range of catalytic activity.  The 
most eye-catching result is probably that Fe2+ exhibits the highest catalytic activity rate  
Metal Used In 
Buffer 








2+ 0.0052 +/- 0.00035 0.00342 +/- 0.00048 0.657692 
Fe
2+ 0.0038 +/- 0.00059 0.01845 +/- 0.00237 4.855263 
Mn
2+ 0.0039 +/- 0.00044 0.01435 +/- 0.00201 3.679487 
Mg
2+ 0.0015 +/- 0.00017 0.00013 +/- 0.00008 0.866667 
Ca
2+ 0.0019 +/- 0.00012 0.00335 +/- 0.00062 1.763158 
Co
2+ 0.0049 +/- 0.00036 0.01903 +/- 0.00599 3.883673 
Zn
2+ 0.0037 +/- 0.00062 0.01715 +/- 0.00403 4.635135 
Table 1. The Km, kcat, and kcat/Km values for the assays performed using various 
metals. 
 
of all seven metals tested, giving the highest kcat/Km value.  To those familiar with 
MetAP, this might seem surprising, considering that in the past, Co2+ has been 
understood to be the native eMetAP metal co-factor (6).  However, in more recent 
times, it has been shown that instead, Fe2+ is the preferred metal for eMetAP, and our 
results are in line with this finding (71).  In our assays, Zn2+ also exhibited quite high 
catalytic activity, as did Mn2+.  As stated previously in this document, Zn2+ is considered 
the native co-factor in yeast, but it is quite intriguing that it is demonstrably preferred 
over Co2+ as well in eMetAP.  Mn2+, the other metal with relatively elevated observed 
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activity levels, is also shown in the literature to be capable of activating MetAP 
efficiently, so its high level of activation is not surprising.   
 
 The Co2+-MetAP is the most prevalently used metalated form in in vitro studies 
(6).  However, as others have shown, activity is maintained (and in some cases 
enhanced or inhibited) using other divalent metals, including Zn2+, Mn2+, Ni2+, Mg2+, 
Ca2+, Cu2+ and Fe2+(6, 10, 12, 20, 22, 23, 76).  In the case of yMetAP, Zn2+ is the 
enzyme providing the optimal level of activation (23).  In eMetAP, Fe2+ has been found 
to be the metal most favored by the enzyme (71).  Further, the hMetAP type II is 
considered to prefer Mn2+ over all other divalent metal ions (67).   Therefore, our studies 
serve not only as support for those previously observed results in eMetAP, but also as a 
comprehensive assessment of eMetAP with all divalent metals (except Cu2+) used 
previously in the literature.  Our findings of Fe2+ being the most potent activator of 
MetAP is very much in agreement with those of Chai et al. (2008) that show Fe2+ is 
probably the native co-factor of MetAP (71).  Moreover, our observation that Ca2+ does 
not facilitate significant enhancement of MetAP activity is also what Chai and colleagues 
noted, as well as other groups (71).  In the case of our Mn2+ assays, the high levels of 
activation and activity, as defined by kcat / Km were expected.  Mn
2+ has been shown to 
bear preference to various MetAPs, including yMetAP, hMetAP-II, eMetAP, and 
Pyrococcus furiosus MetAP Type IIb (pfMetAP-IIb) (71, 76) , and has been shown to 
bind preferentially in the active site by Li and Chang (1996) and D’Souza et al. (2002) 
(28, 76).  The fact that Ni2+ activates eMetAP most poorly is not that surprising.  It has 
been shown that although it is capable of activating eMetAP, the results are minimal 
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(27).  What’s more is that if the enzyme is depleted of its metal, and then re-metalated 
by Ni2+, activity is almost negligible (27).  In other types of MetAP, like bstMetAP-Ia, Ni2+ 
has even been found to inhibit activity (77).  
 
We were slightly surprised by the result of Mg2+-containing assays having such 
low amounts of MetAP activity, only marginally greater than Ni2+ which has been 
observed to be a poor activator of MetAP (77).  In porcine kidney MetAP (pkMetAP), 
Mg2+ has been found to facilitate activity to a great extent, as is the case with bovine 
lens MetAP (77).  Though it may not have been expected to be a particularly strong 
outlier, the fact that Mg2+ performed so relatively poorly is contrary to what has been 
seen in other organisms, like Bacillus stearothermophilus MetAP (bstMetAP) (77).  
However, with hMetAP-IIb, Yang et al. (2001) found Mg2+ only a moderate activator of 
MetAP, especially in comparison to Co2+ and Zn2+, which in our assays, proved quite 
efficacious (78).  However, it was more unexpected that our Zn2+ assay demonstrated 
increased MetAP catalysis over Co2+, as other studies have shown that Zn2+ confers 
significantly weaker activity in eMetAP versus Co2+, one of the reasons Co2+ becoming 
the classically used metal of choice with MetAP (78).  However, as mentioned 
previously, Zn2+ is the preferred metal in yMetAP, and so it’s fostering of elevated 
catalytic activity may be more widespread amongst other organisms and warrants 
further study. 
 
 If one takes these results as a whole, what can be seen in a broad sense is that 
all divalent metals tested facilitate catalytic functioning by MetAP.  Though some metals, 
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like Ni2+ did so quite minimally, there still existed catalysis.  Clearly, the ‘one metal, one 
enzyme’ belief that researchers previously held for metalloenzymes may require some 
revision.  If this were true, then there would have been much different results in our 
assays, especially based on our care to insure that no metal contamination was present 
during our assays. One, perhaps two of the divalent metals tested, would have fostered 
MetAP activity quite appreciably, while the rest would have more or less remained at the 
same low catalytic levels, indicating a more definitive metal for our enzyme.  It may 
simply be the case that MetAP, and possibly other metalloproteases, are capable of 
functioning within a variety of metalated-environments, effectively adapting to the 
surroundings of the organism.   
 
2.3. MetAP: A Moonlighting Protein? 
 It is becoming more widely accepted that the one gene – one protein – one 
function rule is less applicable to complex biological systems of higher organisms (79).  
It has been reported in a number of journal articles that many proteins can be involved 
in cells in processes or structures that are not related to their established or normally 
“main” or originally described function [Figure 20].  This does not even include the many 
instances of where proteins have undergone gene fusions, homologous but non-
identical proteins, splice variants, proteins whose post-translational modifications can 
vary and proteins that have a single function but can operate in different locations or 
utilize different substrates (79).  These proteins are called “moonlighting” proteins since 
other functions for them have been detected in addition to their first described function. 
Thus, it is always exciting to find an alternative role for a protein under study. 
 40 
 
Figure 20. Examples of “moonlighting” proteins and their secondary biological activity. 
<Based on data from reference (79)> 
 
 Based on the interest in MetAP within our laboratory, we are always curious to 
know as much about an enzyme as possible.  One area that has not been investigated 
is MetAP’s activity in other biochemical domains.  Its role as a metalloprotease involved 
in NME has been almost definitively stated in the literature, however, one known 
alternative function of MetAP does exist.   In rats, rat initiation factor-2 associated 
protein (p67) plays a vital in regulating translation through preventing the 
phosphorylation of the α subunit of eukaryotic initiation factor-2 (eIF-2).  However, the 
human homologue, was found to exhibit activity MetAP-like activity, with similar kinetics, 
substrate specificity and even divalent metal-dependance (80).   Human p67 (Hp67) has 
even been found to bind the natural product potent MetAP inhibitor, fumagilin, boosting 
Hp67 obstruction of eIF-2 α subunit phosphorylation (81).  With this unique function in 
mind, we hypothesized whether MetAP has the capability of hydrolyzing substrates not 
previously thought suitable for it to act upon.  Since we were already investigating the 
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functional implications of phosphonates as possible transition-state inhibitors of MetAP, 
we wondered whether phosphate-containing substrates could be processed by MetAP 
at all.  Therefore, we evaluated the compounds 4-nitrophenyl-O-phosphate (4NP) and 
bis(4-nitrophenyl)phosphate (BNPP), since both had been shown to be acted upon by a 
variety of enzymes (82, 83, 84), we speculated whether MetAP could also treat those 
compounds as substrates and yield free p-nitrophenol, seen as a typical yellow colour in 




 The compounds 4-nitrophenyl-O-phosphate (> 97% purity) and bis(4-
nitrophenyl)phosphate (> 95% purity) were purchased from Sigma Aldrich (St. Louis, 
MO).  Recombinant E. coli MetAP was obtained from R&D Systems, Inc. (Minneapolis, 
MN).   
2.3.1.2. MetAP Phosphatase Assays 
 The assay procedure specified in Section 2.2.2.2. was modified to utilize the 
SpectraMax 340 microplate reader’s capacity to read absorbance rather than 
fluorescence as done previously in these studies.  This was done with the appropriate 





























Figure 21. The compounds 4NP and BNPP. 
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clear 96-well microplate rather than a black opaque one.  A buffer solution was then 
prepared similarly as in Section 2.2.2.2.  However, to the 96-well microplate, 1.0 mM of 
4NP or BNPP was added rather than Met-AMC as the substrate.  The assay was then 
begun by reading the UV absorbance over time (72 h).  
 
2.3.2. Results and Discussion 
2.3.2.1. MetAP Phosphatase Activity 
 Initially, it was quite frustrating because there was no change in absorbance after 
the usual assay run times (30 minutes) with either 4NP or BNPP.  So therefore, the 
assay times were increased from 30 minutes to an hour, then from an hour to two 
hours.  After two hours, there was an ever-so-slight change in absorbance, but it had to 
be magnified within the Softmax software in order to see it with any worthwhile 
resolution.  As we were frustrated not having seen any significant catalytic activity of 
MetAP during the 4NP / BNPP assays, we moved on to perform other experiments in 
another area of the lab.  However, the 96-well microplate containing the 4NP / BNPP 
assay mixtures were forgotten in the microplate reader.  As it happened, a group from 
another lab had to use the microplate reader, and inadvertently took the microplate from 
the reader and placed it in the 37 oC oven without inquiring, with the thought to save the 
contents from decaying at room temperature as their own assays required physiological 
conditions and temperatures.  About three hours elapsed and upon our return to this 
area of the lab, the other group was still using the reader, and alerted us to what had 
transpired.  Recovering the microplate, we saw that the wells containing the reaction 
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mixture had turned slightly yellow.  After an endpoint reading of these wells and 
comparing those numbers to newly prepared 4NP / BNPP-containing wells that had not 
had any enzyme added yet, it was clear that pNP had been liberated from our 
substrates.  With this, our approach to the 4NP and BNPP assays had unquestionably 
changed.   
 
 Rather than continuously following MetAP catalysis of 4NP and BNPP, we 
decided to take endpoint readings every 15 minutes as it seemed that the accrual of 
free p-nitrophenol was not sufficiently rapid to monitor with the kinetic setting of the 
microplate reader.  As well, our assays were run at both room temperature and 37 oC, 
to see if there was indeed a difference when run at physiological temperature based on 
what had seemed to happen in the oven [Figures 22 and 23].  
 
MetAP Catalyzed pNP Accumulation (uM) 























Figure 22. The accumulation of pNP through MetAP activity on 4NP and BNPP (Blue: 4NP 
[1.0 mM]; Magenta: BNPP [1.0 mM]; Yellow: 4NP [1.0 mM] (No Enzyme); Light Blue: BNPP 
[1.0 mM] (No Enzyme)) at 25 oC over 72 hours. 
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MetAP Catalyzed pNP Accumulation (uM) 




















Figure 23. The accumulation of pNP through MetAP activity on 4NP and BNPP (Blue: 4NP 
[1.0 mM]; Magenta: BNPP [1.0 mM]; Yellow: 4NP [1.0 mM] (No Enzyme); Light Blue: BNPP 
[1.0 mM] (No Enzyme)) at 37 oC over 72 hours.  
 
 As can be seen from viewing tables Figures 22 and 23, the results indicate that 
MetAP had catalyzed the hydrolysis of the 4NP and BNPP molecules.  This is further 
supported with Figure 23, a photograph taken of the clear 96-well microplate used in the 
experiments housing the assay mixtures after 72 hours – the characteristic yellow 
colour indicates pNP formation [Figure 24].  Moreover, this hydrolysis is greater at 
higher temperature, which is expected in most enzymatic reactions.   
 
Figure 24. The yellow colour in the bottom center of the clear 96-well microplate is 
indicative of reactions with 4NP / BNPP having formed free pNP. 
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BNPP appears to be better processed than 4NP, probably based on its size – the two 
nitrophenyl groups create much more hydrophobic interactions, while the extra nitro 
group may also foster greater polar interactions in the active site of MetAP than the 
single one present on 4NP.  This appears to be in agreement with the heightened 
inhibitory potency of BNPP against 4NP observed in Section 2.4.2. (to be discussed 
later).  Conversely, one might have assumed prior to performing the experiments, if 
MetAP would indeed act upon either of these substrates, the size of BNPP versus 4NP 
may have prohibited it from being processed to the same extent as 4NP based on its 
size being almost twofold larger, but this could be explained simply based on MetAP’s 
active site being more than adequately wide enough to have room for BNPP’s entry.  
The one unusual result, in spite of its accordance with what was previously observed in 
terms of continuous kinetic monitoring, is that it takes approximately 12 hours to notice 
a significant change in pNP concentration in both substrates we examined.  Up until that 
point, MetAP does not seem quite as apt at dealing with these substrates, in spite of 
their rapid blocking of activity when treated as inhibitors.  This might be due perhaps to 
what was mentioned concerning the interaction of moonlighting proteins with different 
types of molecules, as oppose to their native substrate, which may cause the enzyme in 
question to exhibit alternate biochemical roles (79).  
 
These observations represent a novel catalytic reaction of MetAP, an enzyme 
previously believed to be only able to process substrates containing N-terminal Met 
residues.  Further investigation is definitely merited especially to determine if this 
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phosphodiesterase reaction is a physiologically important reaction or just a laboratory 
curiosity.  
 
2.4. Phosphorus- and Sulfur-Based Probes of MetAP 
 
 
 Based on our interest in molecular probes of MetAP, we decided to synthesize 
and purchase a series of compounds that contained phosphorus- and sulfur-based 
functional groups to assay with MetAP and to examine what happens to the enzyme in 
their presence, specifically investigating whether they were capable of inhibiting MetAP 
catalytic activity or not.  Our rationale was based on our previous work on the use of 
phosphonate compounds previously demonstrated to bind to the active site of MetAP, 
as well as studies that demonstrated sulfur-containing molecules also successfully 
decreased metalloprotease enzyme activity (46, 65).  The compounds used are all fairly 
simple in chemical structure.  Our intent was to understand the structure-activity of their 




The phosphorus- and sulfur-based probes purchased were: Aminomethane 
sulfonic acid (97%) (Sigma Aldrich, St. Louis, MO), Aminomethylphosphonic acid (99%) 
(Sigma Aldrich, St. Louis, MO), Methylphosphonic acid (98%) (Sigma Aldrich, St. Louis, 
MO), Pentane sulfonic acid (97%) (Sigma Aldrich, St. Louis, MO), Methylene 
diphosphonic acid (98%) (Sigma Aldrich, St. Louis, MO), Iminobis(methylphosphonic) 
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acid (97%) (Sigma Aldrich, St. Louis, MO), p-nitrobenzenesulfonic acid (98%) (Sigma 
Aldrich, St. Louis, MO), para-toluene sulfonic acid (99%) (J. T. Baker, Phillipsburg, NJ), 
4-Nitrophenyl-O-phosphate (97%) (Sigma Aldrich, St. Louis, MO), bis(4-
nitrophenyl)phosphate (>95%) (Sigma Aldrich, St. Louis, MO) and Triethyl 
phosphonoacetate (>97%) (Sigma Aldrich, St. Louis, MO).   
 
 Diethyl phosphite (98%), valeraldehyde (97%), (diphenylmethyl)amine (97%), 
dichloro-5,6-dicyanobenzoquinone (DDQ) (98%), and anhydrous toluene (99.8 %) were 
obtained from Sigma Aldrich (St. Louis, MO).  4 Å crushed molecular sieves were 
purchased from EMD Chemicals Inc. (San Diego, CA).  Anhydrous N,N-Dimethyl 
formamide (DMF) (>99%) was purchased from Caledon Laboratories Ltd. (Georgetown, 
ON). 
 
Commercially obtained recombinant E. coli Methionine Aminopeptidase was 
obtained from R&D Systems, Inc. (Minneapolis, MN).  The fluorogenic substrate 7-
amido-4-methyl coumarin was acquired from Bacham Bioscience (99%) (King of 
Prussia, PA).  96-well black opaque microplates were obtained from Corning Inc. 
(Corning, NY).  
 
All solvents were evaporated in vacuo on a rotary evaporator unless otherwise 




2.4.1.2. Synthesis of an Aminophosphonate 
 Besides commercially purchasing our compounds, we decided to try and make 
one as well.  An earlier report by Yadav et al. at the Indian Institute of Chemical 
Technology, Hyderabad, India, indicated the facile use of microwave synthesis in a one-
pot synthesis of alpha-amino phosphonates, and we decided to synthesize an analogue 
using their method as well (85).  We focused on the synthesis of the norleucine 
phosphonate, an analogue that did not contain the thiomethyl functionality.  This 
analogue had been previously synthesized and crystallized with MetAP, as reported by 
Lowther et al., however, the inhibitory potency of this compound was not assessed at 
that time (46). 
 
2.4.1.3. Synthesis of (Diphenylmethyl)norleucine aminophosphonate diethyl ester 
 KSF clay powder (1.5 g) (Sigma Aldrich, St. Louis, MO) was added to a 
microwave reaction vessel with a magnetic stir bar.  To this was added 644 ul (0.005 
mol) diethyl phosphite (Sigma Aldrich, St. Louis, MO), 532 ul (0.005 mol) valeraldehyde 
(Sigma Aldrich, St. Louis, MO), and 861 ul (0.005 mol) (diphenylmethyl)amine (DPM – a 
protecting group) (Sigma Aldrich, St. Louis, MO).  Anhydrous dimethylformamide (DMF) 
(Caledon Laboratories, Georgetown, ON) was added until the total reaction mixture was 
5 mL. At this point, the microwave pyrex tube was sealed with a wax-bottom top 
specifically made for use with microwave tubing, and set in the microwave to undergo 
irradiation at 150 oC for 10 minutes.  After completion and cooling of the solution, the 
reaction mixture was evaporated, dried and re-dissolved in chloroform, then eluted on a 
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silica gel column with a mixture of ethyl acetate – hexane (3:7) to afford the protected 
norleucine aminophosphonate.     
 
 
(Diphenylmethyl)norleucine aminophosphonate diethyl ester yield was 751 mg (85%).   
Rf (EtOAc / Hexanes 3:7) 0.11; 
1H NMR (500 MHz, CDCl3) δ (relative to TMS, 0.00  
ppm) 0.85 (m, 3H, CH3 from alkane chain), 1.2-1.33 (m, 6H, CH2 alkane, Cβ, Cγ,  
Cδ), 1.24 (m, 6H, OCH2CH3), 2.75 (m, 1H, Cα), 4.08 (m, 4H, POCH2), 5.25 (s, 1H,  
Ph2CH-), 7.20-7.35 (m, 10H, arene), LRMS (ESI) calculated for C22H32NO3P:  
 389.2120, observed at 390.22 (M+H
+).  
 
2.4.1.4. Norleucine aminophosphonate diethyl ester 
  The following procedure was adopted from a previous graduate student in our 
laboratory, Dr. Peter Sampson (87).  A solution of anhydrous toluene (3 mL) (Sigma 
Aldrich, St. Louis, MO) and 2 g of 4 A crushed molecular sieves (EMD Chemicals Inc., 
San Diego, CA) (stored in a 100 oC oven overnight) was added to a double-neck round 
bottom flask and placed in an argon atmosphere, with a thermometer placed in one 
neck and the other kept sealed.  After 15 minutes, 0.038 g (5 mmol) of the DPM-
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protected compound was added, followed by the addition of 0.34 g (1 mmol) of DDQ 
(Sigma Aldrich, St. Louis, MO) after which the complete reaction mixture was heated to 
60 oC for 2 hours.  The flask itself was covered with aluminum foil and the fume hood 
that this experiment took place in was kept in darkness as the conditions called for no 
light.  Initially, the solution was deep red, however, after the 2 hours elapsed, the 
reaction mixture took on a more orange-ish appearance, and little flecks of purple 
precipitate could be seen.  The mixture was then cooled to room temperature, and 
filtered on a column with Brockmann 1 basic alumina, washed with toluene to elute the 
newly deprotected aminophosphonate.  After removing the toluene in vacuo, a yellow oil 
remained, which was dissolved in 10 ml diethyl either and 10 ml 0.1 N HCl.  The mixture 
was stirred vigorously for 6 hours, followed by separating the phases using a separatory 
funnel.  Each phase was washed twice with the other solvent being used, so in the case 
of diethyl either, this phase was washed with the HCl, and vica versa (2 x 5 ml).  
Combining the aqueous layers and then evaporating the HCl gave a hydrochloride salt 
of norleucine aminophosphate as a yellow oil (236 mg).   
 
 
Norleucine aminophosphonate diethyl ester yield was 23.6 mg (31%).  Rf (EtOAc /  
 
Hexanes 3:7) 0.09; 1H NMR (500 MHz, CDCl3) δ (relative to TMS, 0.00 ppm) 0.85  
 
(m, 3H, alkane CH3), 1.15-1.35 (m, 12H, methylene and OCH2CH3), 3.60 (m, 1H,  
 
tentative NHCHPO), 4.10 (m, 4H, POCH2), 7.30 (broad s, NH); LRMS (ESI)  
 
calculated for C9H22NO3P: 223.1337, observed at 224.15 (M+H
+). 
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2.4.1.5. Inhibitor Assays 
 All assays run with the molecules purchased and synthesized were performed as 
specified in Section 2.2.2.2., with the exception of Co2+ being the metal used.  All 
compounds were dissolved in 3% - 10% DMSO solution, and added in diminishing 
concentrations starting from 50 uM to the buffer solution, sequentially decreased in 20% 
decrements down to approximately 0.5 uM.  DMSO controls were used to verify that 
levels of DMSO up to 10% showed no effect on normal activity of MetAP.  IC50 values 
were determined using the GraFit6TM software for Windows. 
 
2.4.2. Results and Discussion 
2.4.2.1. Synthesis of norleucine aminophosphonate diethyl ester 
The protocol of Yadav et al. made use of montmorillonite KSF clay as a catalyst, 
as in more recent times, clay and zeolite catalysts are becoming more commonly used 
in organic chemistry because they are inexpensive, environmentally compatible, 
reusable, operationally simple, non-toxic, and non-corrosive while offering greater 
selectivity and ease of isolation (85).  They are quite popular among those performing 
anionic reactions, Diets-Alder reactions, acid-catalyzed reactions, aromatic chlorination 
and nitration transformations (85, 86).  So, in creating the DPM-protected norleucine 
phosphonate, we utilized KSF clay in our microwave irradiation synthesis.   
 
After initially synthesizing (diphenylmethylamino)norleucine phosphonate diethyl 
ester using microwave irradiation, we had to remove the DPM group.  This had been 
previously performed in our laboratory by Dr. Peter Sampson, a former graduate 
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student, whose results were published (87).  At the time, this was done to answer the 
question of how to readily remove the DPM protecting group, frequently used for its 
stability in strongly acidic conditions, in situations where mildly acidic conditions must 
prevail.  Though the option of exposing our DPM-protected compound to powerful acid 
to remove it existed, we could not carry this out because of the possible hydrolysis of 
the ethylene groups on the phosphonate oxygens.  Therefore, we removed DPM 
employing an oxidative approach, whereby the secondary amine is oxidized to an imine 
that can then be put in mild acid and the DPM hydrolytically removed (87).  This was 
accomplished through reacting our DPM-protected compound with DDQ, a high 
oxidation potential molecule that has seen much use in organic synthesis as a 














Though we successfully synthesized the aminophosphonate protected derivative 
of norleucine, being norleucine aminophosphonate diethyl ester, this reaction took quite 
a while to optimize.  Initially, it was not understood just how integral maintaining an 
argon atmosphere was to this step.  Initial reaction execution was performed by only 
bubbling argon in to the toluene / molecular sieve solution for 15 minutes, and then 
carrying out the reaction.  This gave shockingly low yields (approximately 5%).  
Moreover, it was also quite important to consistently maintain the 60 oC temperature 
requirement.  A heat gun was used first in order to heat the reaction, as it was important 
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to us not to potentially damage the phosphonate through fragmentation.  However, it 
was not possible to sustain the temperature needed with any kind of stability using this 
approach.  So, once we switched to heating using a water bath, in concert with the 
argon atmosphere, yields dramatically increased, probably fostered by the persistent 
argon infusion as well.   
 
Finally, it must be noted that purifying anything involving the DPM group is very, 
very difficult.  Not only does it tend to contaminate every fraction you purify, in spite of 
how fine you attempt to resolve your purification, but it even remains affixed to the Mass 
Spectrometer so that samples that do not include DPM still appear to have strong DPM 
MS signals present.  Exceptionally low flow rates were eventually utilized to success, 
but the entire procedure took an incredibly long period of time, and is inefficient because 




2.4.2.2. Phosphorus- and Sulfur-Based Compounds as Inhibitors of MetAP 
Viewing Table 2 along with Figure 25 gives the initial impression that the larger 
and more complex a molecule is, the more effectively it behaves as an inhibitor, with the  
largest molecule assayed, bis(4-nitrophenyl)phosphate acting as the most powerful 
compound acting against MetAP catalysis.   If this is correct then the greater number of  
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Figure 25. The compounds used as possible inhibitors of MetAP.  
 
Compound IC50 (µM) 
Bis(4-Nitrophenyl)Phosphate 1.9 +/- 0.30 
4-Nitrophenyl Phosphate 3.2 +/- 0.41 
Triethyl Phosphonoacetate 4.7 +/- 0.67 
Iminobis(methylphosphonic) Acid 5.2 +/- 0.39 
p-nitrobenzenesulfonic acid 8.2 +/- 0.72 
Methyl-p-toluene sulfonate 7.1 +/- 0.45 
Methylene Diphosphonic Acid 10.2 +/- 0.62 
Pentane Sulfonic Acid 12.8 +/- 1.0 
Norleucine Aminophosphonate 
Diethyl Ester 11.4 +/- 0.69 
 (Aminomethyl)-phosphonic Acid 10.5 +/- 0.47 
Aminomethane Sulfonic Acid 12.5 +/- 1.1 
Methylphosphonic Acid 12.9 +/- 0.9 
Table 2. IC50’s (uM) of the phosphorus- and sulfur-based compounds  
examined as possible inhibitors of MetAP 
 
interactions and bonding events that occur within the active site of an enzyme with a 
given molecule, the more tight the binding, and the greater inhibitory value that 
molecule has as an inhibitor.  Based on the similar IC50 values determined for 
(aminomethyl)phosphonic acid  and the aminomethanesulfonic acid it appears that both 
these functional groups can contribute somewhat to inhibitor binding.  It is possible that 
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the phosphate-possessing group would be more similar to the transition state produced 
during a MetAP catalytic event.  
 
It is interesting to note that the racemate of norleucine aminophosphonate diethyl 
ester was not highly active as an inhibitor of the enzyme using Met-AMC as an assay 
substrate.  Once dissolved (which took a higher concentration of DMSO than the other 
compounds, and much more tedious mixing, in spite of it being a hydrochloride salt like 
some of the others commercially purchased) and assayed, it exhibited a fairly weak IC50 
relative to several of the other compounds, although all compounds were in the 
micromolar range for their IC50 values.  However, for our purposes, this compound 
served as a preliminary norleucine analogue that has a neutral charge on the 
phosphonate, yet still maintains its tetrahedral structure, which might resemble the 
tetrahedral intermediate in the enzymatic reaction.  However since it lacks the negative 
charge on the oxygen, future studies should test the monoethyl ester as well as the 
completely deprotected norleucine phonsphonate).   Overall, these results allude to the 
fact that phosphate / phosphonate and sulphonate-containing compounds are able to 
inhibit MetAP.  Further studies are warranted with these compounds to enhance 
inhibitory potency which perhaps might be improved by the addition of moieties that 
resemble a di- or even a tripeptide structure.  
 
2.5. Fluorinated Methionine Analogues 
 
 One of the other areas of research our laboratory has interest in is in fluorinated 
amino acid analogues and their effects on protein structure and function.  The 
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substitution of hydrogen for fluorine confers various changes in methionine’s physical 
properties.  Not only does it become more hydrophobic, but the dihedral angle rotary 
energy barrier is significantly reduced as there is a shortening of the carbon-sulfur bond 
(F3C-S) and an increase in the distance of the sulfur-carbon (S-CH2-R) bond (88).  As 
well, electron and charge density are diminished, causing native state steric interactions 
with other neighboring molecules to be modified (88).  However, it has also been stated 
that fluorine is “relatively nonsterically demanding”, and in certain instances, can replace 
hydrogen atoms of biological molecules with negligible ramifications structurally, which 
is also beneficial depending on the system under study (89).  Taken together, these 
findings from altering methionine through fluorine addition allows for the creation of a 
very unique probe of the MetAP enzyme.  
 
One of the most exciting ways fluorinated-amino acid analogues have been 
utilized by our group and others is as a means to gather structural information about 
protein structure and interactions by using 19F Nuclear Magnetic Resonance 
Spectroscopy (NMR) (89, 90, 91).  Our laboratory in particular has been quite involved 
in studying the production of and the change in structure in biochemically modified 
proteins, and their interactions with other proteins, with F-Met analogues using this 
technique.  We were inspired to examine whether fluorine incorporation into substrates 
processed by MetAP would be processed at a rate less than non-fluorinated ones (92, 
93).  Therefore, we decided to further develop the Met-AMC assay by synthesizing 
fluorinated analogues of Met-AMC, and assessing whether there was a decrease in 
catalysis based on the presence of fluorine atoms in the thiomethyl functionality in 
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methionine, utilizing the fluorogenic Met-AMC assay.  Our laboratory has observed 
decreased fluorinated methionine N-terminal processing for DFM-incorporated in 
Pseudomonas aeruginosa alkaline protease (AprA) (93).  A similar finding was reported 
by Budisa et al. at the University of Milan with trifluoromethionine (TFM) in fluorinated 
green fluorescent protein (92).  To date, these are the only studies looking at enzyme 






Difluoromethionine (DFM) and Trifluoromethionine (TFM) had been previously 
synthesized in our laboratory by Dr. Mark Vaughan, a former graduate student in our 
laboratory (94) and by Ignace Moya, a current graduate student in the Honek laboratory.   
 
Anhydrous methylene chloride (>99.8%) and 9-fluorenylmethyl N-succinimidyl 
carbonate (97%), 7-amino-4-methyl coumarin (99%) were obtained from Sigma Aldrich 
(St. Louis, MO).  Anhydrous N,N-dimethyl formamide (DMF) (>99%) was purchased 
from Caledon Laboratories Ltd. (Georgetown, ON). 
 
The resins PS-carbodiimide, PS-trisamine, and MP-TsOH were obtained from 
Biotage (Charlotte, NC).   
 
Commercially obtained recombinant E. coli Methionine Aminopeptidase was 
obtained from R&D Systems, Inc. (Minneapolis, MN).  The fluorogenic substrate 7-
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amido-4-methyl coumarin was acquired from Bacham Bioscience (99%) (King of 
Prussia, PA).  96-well black opaque microplates were obtained from Corning Inc. 
(Corning, NY).  
 
All solvents were evaporated in vacuo on a rotary evaporator unless otherwise 
specified.   
 
 
2.5.1.2. FMOC-Difluoromethionine and FMOC-Trifluoromethionine  
FMOC-DFM and FMOC-TFM were previously synthesized in the work of Dr. 
Mark Vaughan, a former graduate student in our laboratory (94) [Scheme 9].  A 10 ml 





bar.  Sodium bicarbonate (22.5 mg, 0.265 mmol) was added to function as a base, 
followed by 50 mg (0.27 mmol) of DFM or 54.5 mg (0.27 mmol) TFM and 90.5 mg (0.27 
mmol) 9-fluorenylmethyl N-succinimidyl carbonate (Sigma Aldrich, St. Louis, MO) being 
added to the solution.  This reaction mixture was then allowed to sit on ice for 1 hour, 
and then was stirred at room temperature overnight.  Afterwards, it was acidified to pH 2 
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using 0.1 N HCl.  Solvents were removed in vacuo, and the aqueous layer was 
extracted with chloroform (3 x 1 ml).  The organic layer was then washed with H2O until 
reaching a neutral pH.  The solution was then dried over anhydrous sodium sulfate and 
evaporated to give a yellow oil.  When checking purity with mass spectrometry and TLC, 
it appeared that unreacted FMOC and DFM / TFM was still present (Rf (CHCl3/EtOAc 
3:7; 0.9 and 0.05).  Therefore, FMOC-DFM and FMOC-TFM were treated as >95% pure 
for the next step of the reaction 
 
The FMOC-DFM and FMOC-TFM compounds created here were 
spectroscopically identical to the compounds produced by Dr. Mark Vaughan in our 
laboratory previously (94).  Our characterizations of both of the currently synthesized 
























FMOC-Difluoromethionine yield was 34.1 mg (85%).  Rf (CHCl3/EtOH 3:1) 0.52; 
1H  
NMR (500 MHz, CDCl3) δ (relative to TMS, 0.00 ppm) 2.06 (m, 1H, CβHB),  
2.32 (m, 1H, CβHA), 2.86 (m, 2H, CγH2), 4.25 (t, 1H, CαH, J = 7.0 Hz), 4.45 (m, 2H,  
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COCH2), 4.56 (m, 1H, fluorene-CH-CH2-)), 5.45 (1H, CONH), 6.81 (t, 1H, CHF2, JHF = 
56 Hz), 7.33 (2H, arene), 7.42 (2H, arene), 7.58 (2H, arene), 7.77 (2H, arene),10.65 (s,  
1H, CO2H); LRMS (ESI) calculated for C20H19NO4F2S (M+) 407.1003 observed at  

























FMOC-Trifluoromethionine yield was 31.5 mg (79%).  Rf (CHCl3/EtOH 3:1) 0.54;  
1H NMR (500 MHz, CDCl3) δ (relative to TMS, 0.00 ppm) 2.03 (m, 1H, CβHB), 2.34  
(m, 1H, CβHA), 2.87 (m, 2H, CγH2), 4.10 (t, 1H, CαH, J = 7.0 Hz), 4.40 (m, 2H, COCH2),  
4.55 (m, 1H, fluorene methine), 5.33 (1H, CONH), 7.32 (2H, arene), 7.39 (2H, arene),  
7.58 (2H, arene), 7.75 (2H, arene), 10.68 (s, 1H, CO2H); LRMS (ESI) calculated for  
C20H18NO4F3S (M
+) 425.0909 observed at 426.4223 (M+H+) (also observed: (M +  
Na+) calculated 448.0806, observed at 448.0984). 
 
 
2.5.1.3. FMOC-Difluoromethionine-AMC and FMOC-Trifluoromethionine-AMC  
The protected fluorinated analogues, 34.1 mg FMOC-DFM (0.084 mmol) and 
33.7 mg ( 0.079 mmol) FMOC-TFM products from the previous step were dissolved in 3 
ml of anhydrous methylene chloride (Sigma Aldrich, St. Louis, MO).  PS-carbodiimide 
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(Biotage, Charlotte, NC; 146.9 mg (2 eq. based on the company’s analysis of 3.8 
mmol/g of resin) was added.  PS-carbodiimide, as reported by Booth and Hodge (95), 
consists of a coupling agent carbodiimide that is attached to a resin bead where the 
coupling reaction takes place [Scheme 10]. AMC (14.4 mg, 0.082 mmol) (Sigma Aldrich, 
St. Louis, MO) was dissolved in 0.3 ml anyhydrous DMF (Caledon Laboratories Ltd., 
Georgetown, ON), which was then added to the resin / TFM / DFM mixture in a 
microwave test tube.  The complete  
 
Scheme 10  (X = PS-carbodiimide resin)  
 
reaction mixture was then exposed to microwave irradiation for 3 h at 100 oC in the 
Biotage Initiator Microwave (Biotage, Charlotte, NC). Previous experiments determined 
that this temperature and this length of time were optimal to avoid decomposition of the 



































FMOC-Difluoromethionine-7-amino-4-methyl coumarin: Rf (CHCl3 / EtOAc 3:7) 0.60;  
 
contamination with some unreacted AMC which co-purified with the compound. Semi- 
 
pure product was used in the next step, which was the removal of the FMOC group  
 
followed by purification. 1H NMR (500 MHz, CDCl3) δ (relative to TMS, 0.00 ppm)  
 
tentative assignments: 2.23 (m, 1H, CβHB), 2.30 (m, 1H, CβHA), 2.90 (s, 3H, coumarin- 
 
CH3), 2.97 (m, 2H, CγH2), 4.02 (t, 1H, possible fluorene methine), 4.11 (t, 1H, CαH, J =  
 
7.0 Hz), 4.31 (m, 2H, fluorene-CH-CH2), 5.95 (s, 1H, possible coumarin arene), 6.35  
 
(broad s, 1H, possible NH of amide), 6.75 (t, 1H, CHF2, JHF = 57 Hz), complex arene  
 
region 7.23-7.7 unable to deconvolute due to complex mixture, 8.02 (broad s, 1H,  
 
possible CαNH); LRMS (ESI) calculated for C30H26N2O5F2S (M
+) 564.1530 observed at  
 
565.1791 (M+H+). (Also observed: (M + Na+) calculated 587.1428, observed at  
 




































FMOC-Trifluoromethionine-7-amino-4-methyl coumarin: Rf (CHCl3 / EtOAc 3:7) 0.63; 
1H  
 
NMR (500 MHz, CDCl3) δ (relative to TMS, 0.00 ppm) 2.10 (m, 2H, CβH2), 2.28 (s, 3H,  
 
CH3), 2.90 (m, 2H, CγH2), 3.96 (d, 2H, fluorene-CH-CH2, J = 6 Hz), 4.05 (t, 1H, CαH, J =  
 
6 Hz), 4.30 (m, 1H, fluorene-methine), 5.93 (s, 1H, arene), 7.23-7.35 multiplets (5H,  
 
arene) 7.57 (2H, arene), 7.73 (2H, arene), 7.94 (2H, arene), 8.12 (s, 1H, CαNH), 8.83 (s,  
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broad, NH) LRMS (ESI) calculated for C30H25N2O5F3S 582.1436, observed at 583.1713  
 
(M+H+). (Also observed: (M + Na+) calculated 605.1334, observed at 605.1464; (M +  
 
K+) calculated 621.1073, observed at 621.1348).  
 
 
2.5.1.4. Removing Unreacted AMC 
In order to remove unreacted AMC, the scavenging resin MP-TsOH (Biotage, 
Charlotte, NC) was used [Figure 26].  FMOC-DFM-AMC and TFM-FMOC-AMC were 
dissolved in 5 ml chloroform, to which we added the resin to fill the bottom portion of the 
round bottom flask, qualitatively.  This was then stirred at room temperature until no  
 
Figure 26. MP-TsOH Resin (Biotage, Charlotte, NC) 
 
AMC was present in the solution as based on visualization using thin-layer 
chromatography (TLC) (Rf (CHCl3/EtOAc 3:7) of AMC – 0.51, DFM-AMC, 0.06). If AMC 
was still present, small amounts of the resin was added again, and stirring continued.  
The reaction was finished after approximately 30 minutes, and the resin removed by 
vacuum filtration. 
 
2.5.1.5. Removing FMOC 
FMOC is a base-sensitive protecting group, so in order to remove it, the PS-
trisamine resin was added to the crude FMOC-DFM-AMC and FMOC-TFM-AMC 
mixtures.  Removal of base-sensitive FMOC was done using 0.34 g (10 eq. ) of PS-
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trisamine resin (Biotage, Charlotte, NC) (based on the company’s analysis of 3.9 mmol / 
g of resin) [Figure 27] an approach suggested before by Booth and Hodge (95) and by 
personal communication with the technical division of Biotage, Inc. . The reaction 
mixture containing FMOC-DFM-AMC was dissolved in anhydrous methylene chloride 
(3mL) (Sigma Aldrich, St. Louis, MO) and placed in a microwave test tube.  The resin 
was then added and the entire mixture was exposed to microwave irradiation for 3 
minutes at 100 oC.  TLC confirmed the absence of FMOC in the reaction mixture (Rf 
(CHCl3/EtOAc 3:7) FMOC – 0.9, DFM-AMC – 0.05) 
 
Figure 27. The PS-Trisamine resin from Biotage (Biotage, Charlotte, NC) 
 
Once FMOC was removed, DMF-AMC and TFM-AMC samples were purified 
using the Biotage Flash System (Biotage, Charlotte, NC) before physical 
characterization using NMR and mass spectrometry.  Unfortunately, this did not 
adequately purify the compounds, with some impurities still left in the reaction mixture.  
Whether it was because of the lack of reaction completion with the resins, or simply 
hydrolyzed AMC confounding the refinement, the compounds were not pure.  Therefore, 
in order to obtain a finer resolution, a miniature gravity column was made using a 
Pasteur pipette packed with silica gel and cotton.  Purification was much more lengthy 
(at least 8 hours for each compound), but the end result was a pure product.  Even still, 
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the final yields for the truly pure DMF-AMC and TFM-AMC were 1.2% and 1.7% (1.1 mg 























Difluoromethionine-7-amino-4-methyl coumarin yield: 1.1 mg; Rf (CHCl3 / EtOAc 3:7)  
0.12; 1H NMR (500 MHz, CDCl3) δ (relative to TMS, 0.00 ppm) 2.76 (m, 2H, CβH2),  
2.88 (m, 2H, CγH2), 2.40 (s, 3H, CH3), 4.30 (m, 1H, CαH), 6.06 (s,1H, arene), 6.84 (t,  
1H, CF2H, JHF = 56 Hz), 7.55 (m, 1H, arene), 7.70 (m, 1H, arene), 7.98 (1H, arene),  
8.16 (broad s, 1H, NH), 9.76 (broad s, 1H, NH); LRMS (ESI) calculated for  

























Trifluoromethionine-7-amino-4-methyl coumarin yield: 1.7 mg; Rf (CHCl3 / EtOAc 3:7)  
 
0.1; 1H NMR (500 MHz, CDCl3) δ (relative to TMS, 0.00 ppm) 2.45 (s, 3H, CH3), 2.57  
 
(m, 2H, CβH2), 2.67 (m, 2H, CγH2), 4.26 (m, 1H, CαH), 6.17 (s, 1H, arene), 7.58 (m,1H,  
 
arene), 7.66 (m,1H, arene), 7.74 (m,1H, arene), 8.03 (1H, tentative NH3
+); LRMS (ESI)  
 
calculated for C15H15N2O3F3S: 360.0755, observed at 361.0734 (M+H
+). 
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2.5.2. DFM-AMC / TFM-AMC Assay 
 To get a sense of whether our synthesized fluorinated methionine analogues are 
processed by MetAP with any level of efficiency, we decided to assay them using the 
Met-AMC assay.   
 The DFM-AMC / TFM-AMC Assay was performed as outlined in Section 2.2.2.2. 
in the Met-AMC assay.  However, DFM-AMC and TFM-AMC were dissolved in 20% and 
18% DMSO solution, and added to the buffer solutions in concentrations up to 1.5 uM.  
For comparison, Met-AMC was added in the same way.  Kinetic constants Km and kcat 
were determined using GraFit6TM software for Windows through non-linear regression 
fitting of the rate v.s. substrate concentration curve (also referred to as the Michaelis-
Menten curve). 
 
2.5.3. Results and Discussion 
2.5.3.1. Synthesis of DFM-AMC and TFM-AMC 
The commonly used fluorenylmethyloxycarbonyl (FMOC) amino protecting group 
was added to DFM and TFM in order to prevent reactions taking place at the amino 
terminal of the analogues when linking them to the AMC chromophore at the carboxyl 
group and additionally to prevent polymerization reactions during the coupling of the 
chromophore to the amino acid.  The chromophore, 7-amino-4-methyl coumarin (AMC), 
was coupled to FMOC-DFM and FMOC-TFM using the PS-carbodiimide resin to create 
FMOC-DFM-AMC and FMOC-TFM-AMC.  Then using the resins PS-Trisamine and MP-
TsOH, the FMOC group of the compounds, and any unreacted AMC, were removed, 
yielding DFM-AMC and TFM-AMC.   
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Overall, the reaction was successful and fairly easy to perform, albeit, the 
purification was quite arduous.  Flash chromatography on a large scale did not 
sufficiently purify DFM-AMC and TFM-AMC for our needs.  Therefore, small-scale 
purification using a gravity column was necessary in order to obtain a finer resolution, 
and yielding truly pure compounds.  Though our final yields DFM-AMC and TFM-AMC 
were quite low (1.1 mg and 1.7 mg, respectively) they were adequate for our 
requirements of characterization and utilization in fluorescence assays.    
 
2.5.3.2. Kinetic Parameters for DFM-AMC and TFM-AMC  
 As Table 3 shows, Met-AMC is superior as a substrate to both DFM-AMC and 
TFM-AMC.  The catalytic efficiency (kcat/Km) is superior to both analogues, and this was 
partially expected.  It has been seen that L-TFM affects processing of N-terminal 
substrates adversely (92, 93), and so the fact that in our experiments, it showed only  







DFM-AMC 0.0073 +/- 0.00085 0.01395 +/- 0.00171 1.91 
TFM-AMC 0.0094 +/- 0.00091 0.01014 +/- 0.00098 0.541 
Met-AMC 0.0051 +/- 0.00042 0.01872 +/- 0.00266 3.67 
Table 3.  The Km, kcat, and kcat/Km of DFM-AMC, TFM-AMC, and MET-AMC. 
 
15% of catalytic processing by MetAP as compared to Met-AMC is not surprising.  The 
additional steric bulk imposed on TFM by the additional fluoride substitution is 
apparently sufficient enough that even in protein systems engineered like lysozyme 
bacteriophage lambda (LaL) to express it, it is much more difficult to integrate and is 
found with fairly low frequency (90).  Its poor performance in these assays are 
consistent with what has been qualitatively observed in protein processing. The DFM-
AMC substrate was processed with efficiency in between methionine-AMC and TFM-
AMC. It is interesting to note that DFM incorporation into proteins is very high, almost 
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suggesting that the two fluorines contribute  little steric  hindrance to the normal 
biochemical processing of this analogue (90).  
 
2.6. Summary 
 We have demonstrated various unique means of querying MetAP activity and 
biochemical character.  Divalent metal activation kinetics and the metal-dependance of 
MetAP has been shown, with Fe2+ seeming to be eMetAP’s native metal co-factor, as 
has been reported in the literature (76).  With this, we have further developed the 
fluorogenic assay of MetAP activity with the chromophore Met-AMC.  We have also 
potentially demonstrated an additional ‘moonlighting’ role of MetAP – phosphatase 
activity - not previously known, and undoubtedly deserving of further investigation.  We 
have also shown MetAP to be inhibited differentially by various phosphorus- and sulfur-
containing compounds, more potently inhibited by those more closely resembling a 
tetrahedral intermediate.  Finally, we have synthesized novel fluorogenic substrates with 
fluorinated substitutions that have advanced our understanding of the substrate 
specificity of Met-AMC, and the effect of fluorination on MetAP catalysis, our enzyme 













Chapter 3. In Silico Chemistry and Molecular Modeling 
3.1.1. Introduction 
One of the most important current uses of molecular modeling is the virtual 
docking of potential ligands on to protein targets so as to design pharmaceuticals in 
silico by identifying new chemical structures that may potentially bind to a protein active 
site and to also optimize lead candidate structures (96).  Docking algorithms are used to 
find lead candidates by attempting to identify the optimal binding mode, termed a 
“pose”, of small molecules on the active site of a macromolecular target.  Thus, virtual 
docking software attempts to find compounds that more strongly bind to a given protein 
target than the natural substrate [Figure 28].  With this, the biochemical reaction 
catalyzed by the macromolecular complex can be inhibited or modified in the hopes of 
 
Figure 28. A desktop view of the Molegro (Molegro ApS, Aarhus, Denmark) virtual 
docking software suite, used in our in silico chemistry experiments. 
 
 70 
eliminating the deleterious effect of continued reaction. 
 
High throughput screening methods are useful to measure the activity of a large 
number of compounds against a specific biochemical target (96, 97).  Unfortunately, this 
practice tends to be costly, and extremely laborious.  However, with the availability of 
3D structures, molecular docking simulations can provide a very useful and practical 
tool in drug-discovery (97).  Using an in silico approach, one is permitted a faster and 
cheaper strategy to identify promising drug candidates by screening virtual entire 
compound libraries in the hopes of finding promising leads.  Once this portion of the 
process is complete, laboratory experimentation, be it synthesis, biochemical assays, 
toxicological assessment, or even clinical trials, can be conducted to further inspect the 
drug candidates identified.  
 
 Virtual screening is based on software docking methods that use an energy-
based scoring algorithm, called a “scoring function”, to identify the energetically most 
favorable ligand conformation when bound to the target (97).  In a broad sense, lower 
energy scores represent better protein−ligand bindings compared to higher energy 
scores.  Molecular docking can be viewed as an optimization tool, meant to identify the 
conformations of compounds that have the tightest binding.  
 
 
As mentioned earlier in this work, molecular modeling and in silico chemistry has 
become more ubiquitous within the drug discovery process over the last 20 years, 
having produced and expanded upon many potential candidate drugs [Figure 29] (97).  
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For example, when viewing Figure 29, taken from a review by Shoichete and his 
collaborators, one sees the target tumorgenic enzyme CDK4, a kinase in cell cycle G1 
phase progression, where the lead inhibitory compounds available for this enzyme were 
immensely improved using molecular modeling techniques (97).  The best inhibitor 
available prior to the studies by the original research group, Honma and colleagues at 
Merck in Japan, had an IC50 of 44 uM (98).  Through molecular modeling, and 
modifications to the lead compounds, Honma et. al. ultimately came up with N-[(9bR)-5-
oxo-2,3,5,9b-tetrahydro-1H-pyrrolo[2,1-a]isoindol-9-yl]-N‘-pyridin-2-ylurea, with an IC50 
of 0.011 uM when tested against CDK4 (98).  This is an absolutely amazing 
improvement that clearly demonstrates the merits of computer-aided drug design and in 
silico chemistry in general.  Such findings have not only been fostered by the availability 
of greater computing power at a lower cost, but also because of the greater availability 
of compound libraries available both publicly and from the private sector (97).   Work 
has typically focused on enzymes and their inhibition (97, 99).  The inhibitors discovered 
usually are quite novel, having little similarity to the enzyme’s known ligands, and most 
having affinities in the low-micromolar range (97).  One of the most exciting exceptions, 
however, has been new sulfonamide inhibitors of carbonic anhydrase II – though they 
are much more potent (nanomolar potency), they are not completely novel (97).  In any 
event, the high number of lead candidates discovered has undoubtedly been enhanced 

































Figure 29. Examples of various lead candidates discovered using virtual 
screening in the last decade.  Enzyme inhibited by the compound shown is in 
brackets. <Adapted from reference (97)>  
 
It is important to note that one of the original criticisms molecular docking faced 
was that it did not sufficiently take into account flexibility of the residues in the active site 
of the protein, and therefore, the reality of a ligand-substrate binding event (99).  A 
different complexion is placed upon the matter entirely when the software evaluates the 
ligand and macromolecular active site as dynamic and in flux, rather than rigid and 
static.  Contemporary software does indeed factor flexibility into scoring, however, this 
creates a much higher number of potential ligand poses and protein side-chain 
conformations to be considered.  Though computing power has increased dramatically 
since the beginnings of molecular modeling, docking remains a very challenging 
dilemma as the high number of possible docking conformations (within the field called 
“poses”) prevents a systematic brute-force approach (100).  Therefore, in order to 
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properly assess potential conformations when docking ligands upon proteins in silico, 
thereby properly handling flexibility, search heuristics are required. It should be noted 
however that the most critical weaknesses in docking programs is the inability of these 
programs to faithfully capture the intermolecular interaction potentials between the 
ligand and the protein. These concerns will be expanded upon later in this chapter. 
 
3.1.2. Molecular Docking and Virtual Screening 
Molegro (Molegro ApS, Aarhus, Denmark) was chosen for the docking and virtual 
screening assays for a variety of reasons.  One reason was the affordability.  Some 
molecular modeling software can run many thousands of dollars, making it more difficult 
for laboratories outside of industry to gain access to these programs.  As well, Molegro 
is available in a very easy to use format for Apple and PC platforms, which means that 
those unfamiliar with operating systems based on UNIX are not prohibited from using it.  
However, most importantly, Molegro is centered around the MolDock scoring function, 
the newest and potentially one of the most accurate and reliable scoring function 
currently available (100) [Figure 30].   
Accuracy of Scoring Functions in 


























Figure 30.  A comparison of docking accuracy with a selection of widely used docking 
algorithms. <Adapted from reference (100)> 
 74 
Released in 2005, MolDock has been shown to identify the correct binding mode 
of flexible ligands 87% of the time in a docking study with a defined subset of ligands 
and proteins (100).  This result surpasses the reliability of other, widely used scoring 
functions, such as GOLD, found to be reliable 78% of the time in the same study, or 
Glide, which had 82% accuracy in distinguishing the correcting binding mode of the 
same flexible ligands (100).  Nevertheless it should be kept in mind that these values 
could vary for these programs depending upon the chosen protein-ligand sets used in 
the comparison. 
 
Various mathematical algorithms are currently in use that search through 
thousands of different poses during the molecular docking process to find the most ideal 
conformation balanced with the most realistic.  Based on the attempt to find the most 
“optimized” solution, these algorithms are referred to as “heuristic search algorithms” 
(100).  The most popular heuristic search algorithms in molecular docking are simulated 
annealing, based on combining the parameters involved in the annealing of solids and 
statistical mechanics (100); tabu search, Glover’s landmark heuristic search algorithm 
which is a procedure that iteratively moves from one solution to another potentially 
better solution within a specific search space (100); and evolutionary algorithms, which 
much like their name denotes, provide a set of solutions to a problem and those most fit 
to answer the problem “outlive” other solutions too costly for their own survival with 
increasing complexity applied to the solutions incrementally (100).   
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MolDock is based on a new search heuristic algorithm, called “guided differential 
evolution” (100).  Guided differential evolution algorithm is a hybrid, combining the 
differential evolution with a cavity prediction algorithm.  Differential evolution (DE), 
introduced by Storn and Price at Berkeley in 1995 (101), is a mathematical technique 
used to find a global minimum, based on computational evolutionary methods, amongst 
large amounts of multivariable and multifactorial data, and does so with precise 
probability (101).  This procedure has seen previous success in its application to 
molecular docking, through its handling of flexible ligands and large macromolecular 
complexes (100).  DE, combined with the use of predicted cavities within sizeable 
protein molecules by restricting the search space to a particular region, allows for quick 
and reliable identification of potential binding modes, or “poses” of lowest energy (100).  
 
MolDock is an extended version of a previous evolutionary-based scoring 
function called GEMDOCK, introduced by Yang and colleagues in 2004, with the 
addition of a piecewise linear potential (PLP) from Gehlhaar (100).  The docking scoring 
function is given by Equation 1: 
Eq. 1. EScore = EInter + EIntra 
where EInter is the ligand-protein interaction energy (100) (Equation 2): 
          Eq.2 . EInter =     Σ       Σ        [ EPLP(rij) + 332.0 qiqj ] 
                                                                          iε  ligand   jε protein                                                ____ 
                                                                                    4r2ij 
 
This equation is applied to all heavy atoms in the ligand and all heavy atoms in the 
protein, including any cofactor atoms and water molecule atoms that might be present 
(100).  The EPLP term is the piecewise linear potential.  It uses two different sets of 
 76 
parameters: one set for approximating the steric (van der Waals) term between atoms 
and the other stronger potential for hydrogen bonds (100).  The PLP is given by 
Equation 3:  
Eq. 3. ETotal = EH-Bond + EInter + ERepulsion + EContact 
EH-Bond  is the contribution to the total energy by hydrogen bonding, EInter is the 
contribution to energy by the total intermolecular forces, ERepulsion is the internal atomic 
repulsion and Econtact is the atomic contribution of contact potentials (100).   This 
powerful equation however, is extended with a further expansion of the definition of 
hydrogen bonding energy, which with MolDock takes into account hydrogen bond 
directionality (previously ignored with earlier scoring functions that account for hydrogen 
bonding energy), given by the H-Factor (Equation 4): 
 
Eq. 4. HFactor = Φ (∆D-H-A; 90
o; 100o) · Φ (∆H-A-AA; 90




In the above equation, a bond is considered a hydrogen bond if one of the atoms 
can donate a hydrogen atom and the other atom can accept it (100).  The EPLP in 
Equation 2 only depends on the distance between atoms.  Therefore, as in Equation 4, 
to take into account the directionality of hydrogen bonding, the geometry of the 
hydrogen bond is examined, and the following factor, HFactor, is multiplied by the PLP 
hydrogen bond strength (100).  AA (the Aacceptor Antecedent) denotes a heavy atom 
connected to the acceptor (A), while D denotes the donor, and H is the specific donated 
hydrogen atom (100). The ramp function Φ is defined as Φ (A; Amin; Amax)  = 0 for A <= 
Amin and Φ (A; Amin; Amax) = 1 for A >= Amax and is linearly interpolated between these 
values for Amin < A < Amax (100).  In the case that it is impossible to calculate one of 
these factors, it is left out (100).  This pertains to cases like hydroxyl groups, where the 
 77 
particular location of the hydrogen is not investigated during docking, and these two 
factors cannot be calculated (100). 
 
In equation 2, the second term describes the electrostatic interactions between 
charged atoms (100).  It is a Coulomb potential with a distance-dependent dielectric 
constant given by D(r) 4r (100). The numerical value of 332.0 constrains the units of the 
electrostatic energy to kcal/mol (100).  For dealing with distances that are less than 2.0 
Å, the electrostatic energy is cut off at the level corresponding to a distance of 2.0 Å to 
ensure that no energy contribution can be higher than the clash penalty.  It is important 
to note that in spite of the electrostatic energy contribution having the theoretically 
predicted magnitude, all other energy terms are experimentally based, and the actual 
binding affinity is not necessarily compatible with total energy (100).  
 EIntra is given by the following (Equation 5): 
Eq. 5. EIntra =          Σ       Σ     EPLP(rij) +     Σ         A[1 – cos(m·Θ – Θo)] + Eclash 
                                         iε  ligand   jε protein                         flexible bonds 
 
 
The double summation is between all atom pairs in the ligand, excluding atom pairs that 
are connected by two bonds or less (100).  The second term is a torsional energy term, 
parameterized according to the hybridization types of the atoms involved in bonding and 
the term responsible for taking into account bond rotability both in ligand structure and 
side chain residue conformational variability.  Θ, the torsional angle of the bond, is not 
necessarily determined uniquely in each instance, but at times, under appropriate 
circumstances, is generally defined based on known bond geometry (100).  Molegro 
treats two types of bonds as rotatable, namely sp2-sp3 bonds and sp3-sp3 bonds.  
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According, for sp2-sp3 bonds, the Θo in Equation 5 is 0.0, m is 6 and A is 1.5, while for 
sp3-sp3 bonds, Θo is π, m is 3 and A is 6.  The last term, Eclash, assigns a penalty if the 
distance between two atoms (more than two bonds apart) is less than 2.0 Å.  Therefore, 
the Eclash term is meant to penalize ligand conformations that are not possible (100).  
This issue is important especially with regards to side chain flexibility, a feature of 
Molegro that will be discussed in greater detail later. 
 
3.1.3. General Experimental 
3.1.3.1. Materials 
Throughout our series of molecular modeling experiments, the following software 
was used: MacSpartan 8.0 (Wavefunction Inc., Irvine, CA) for structure based ligand 
building and MAC Molegro v3.2 (Molegro ApS, Aarhus, Denmark) for docking and 
virtual screening of compounds against MetAP.  All experiments were performed on an 
Apple Mac Pro with two quad-core Intel Xeon “Nehalem” processors (4 x 2 processors = 
8 processors total) with 16GB RAM.   
 
 3.1.3.2. Docking With Molegro 
Docking in our experiments using Molegro was performed as follows: the target 
protein was searched for on the Protein Data Bank (www.rcsb.org), and the 3D 
structure, in the form of a PDB file, was downloaded.  This PDB file was then imported 
into the Molegro work space, usually excluding waters as is the standard procedure in 
most virtual screening and molecular docking studies (96).  Ligands built in Spartan and 
minimized at the B3LYP / 6-31+G* level were then imported in to the same work space.  
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A built-in feature of Molegro is to “prepare” the molecules for docking - correct any 
errors in the PDB file (ie. looking for missing bonds) and the Spartan-built ligand, while 
adding hydrogens to the protein structure, so this was performed next.  Afterwards, the 
‘cavity’, or area of the 3D structure most likely to bind a ligand, was detected 
automatically using Molegro (however, it is worth noting that one also has the option of 
manually selecting the area of the protein you would like to dock with ligands).  
Following this, docking was performed in Molegro.  The only setting typically changed 
from default when using this feature is the number of iterations (changed from ‘15’ to 
‘100’ – the maximum permitted), and the default search space, or the area the software 
uses on the protein to dock ligands – this was changed from the default centre of the 
protein to the specific cavity detected earlier.  After running the docking simulation, the 
results were imported, and evaluated.  Docking scores are reported by MolDock in 
kcal/mol form. 
 
The default reporting of MolDock scores do not factor in all the various elements 
that Molegro uses in arriving at the lowest energy pose of a ligand.  For example, in 
spite of its factoring in forces like van der Waal’s forces and hydrophobic interactions in 
its algorithm, it does not rank the poses generated initially using some of these 
intuitively important scoring factors.  This is probably because the developers of 
Molegro wanted to provide the user with the option of ranking poses with whatever  
factors they wanted to choose, which would probably be different depending on the 
aims of the experiments and the types of compounds and target proteins used in 
docking.  Therefore, in addition to a comparison with the “ReRank score” Molegro 
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provides (however, once more, this does not provide a score complete in terms of all 
potential factors involved in the scoring process), all relevant scoring factors, such as 
short- and long-term interactions, and as to be seen later, in specific cases water 
molecule interactions, were selected, and the poses re-ranked to obtain the most 
accurate pose with the most accurate lowest energy possible.  The pose with the lowest 
energy will be referred to henceforth as the lowest energy pose (LEP). 
 
3.1.3.3. Standard Error 
Before proceeding any further, it was important to find out whether the MolDock 
algorithm gave the same score every time if the ligands and 3D structures, as well as 
settings, remained equal.  Intuitively, one might believe that this is the case, as many 
kinds of software often function like a calculator – the same numbers put in and 
performed with the same arithmetic always yields the exact same answer.  However, 
during preliminary phases of using Molegro, it became apparent that this was not the 
case, and in fact each time a value for the energy of an LEP was given after a docking 
simulation, it was different from the previous one, even if the pose topographically 
appeared to be the same.  To test this definitively, the PDB file 3MAT, a structure 
deposited by one of our previous collaborators Matthews and Lowther at the University 
of Oregon, was imported into Molegro, and its bestatin-based inhibitor, (3R)-amino-(2S)-
hydroxyheptanoyl-L-Ala-L-Leu-L-Val-L-Phe-OMe [Fig ] was docked with the di-
metalated (Co(II)) eMetAP structure according to the procedure in Section 3.3.1.2. 
(discussed later) , with the LEP saved into the workspace, and the docking process 
taking place again with the original ligand.  This process was repeated five times.  
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The energetic score for each pose of the highest energy obtained after the 
simulations run were:  -130.102, -129.323, -126.407, -131.799, and -135.196.  
Therefore, when docking the same ligand against the same substrate in replicate, 
MolDock actually gives a slightly different score after every run.  Calculating the 
standard error gives a scoring variation of approximately 3%.  This seemed strange 
initially, as it appeared visually that the LEPs in each run were in the identical position.  
However, upon further examination, it was the case that there are slight deviations in 
position within the workspace only discernable through precise calculations using inborn 
functions of the Molegro workspace to measure discrete distances and angles.  The 
random nature of the iteration process, a necessity built-in to the algorithm in order to 
prevent bias, is something that probably also contributes to this result (100).  In any 
case, for all molecular docking simulations, to be accurate, all values reported are the 
average of runs in triplicate, and a standard error is assigned where appropriate.   It 
should be added that this variation in energetics in a docking algorithm is likely also 
produced in all docking software although little is mentioned in the scientific literature 
concerning the magnitude of these variations. 
3.2. Assessing Molegro Accuracy 
 In spite of the report that MolDock is the most advanced and reliable docking 
algorithm currently available (96, 100, 102), based on previous experience in our lab, 
and the generally acknowledged consensus that molecular modeling, and in silico 
chemistry in general, is still not as reliable as the ‘lab bench’; it was important to identify 
the confidence level of our Molegro docking results.  Therefore, a three-tier approach 
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was developed in order to examine the accuracy of Molegro in predicting previously 
published results.  In this way, it was believed that if Molegro was faithful in reproducing 
the results, or obtaining very similar results, to published articles, then our own 
experiments with the software could be taken more seriously, and our docking 
predictions might have increased predictive power.  
3.2.1. Experiment #1:  Comparing Previously Published Inhibitor Potency 
With Predicted Molegro Scoring 
 
 In this experiment, it was our desire to assess whether in fact Molegro and the 
MolDock scoring function could predict the order of inhibitor potency of previously 
published small molecule inhibitors.  If it could, then we would expect that the order of 
the energetic scores provided by Molegro would correspond to the order of potency, 
given as an IC50, of the inhibitors.  
 
3.2.1.1. Experimental 
A publication was selected based on fulfilling several criteria: 1) The target of 
inhibition had to be MetAP; 2) The inhibitors used had to be metal dependant or take 
into account the coordinating role that metals play in the active site; 3) There was a 
range of inhibition between the weakest and strongest compounds relative to IC50.  
Therefore, the paper by Hu and colleagues (2004), “Peptidyl Hydroxamic Acids as 
methionine aminopeptidase inhibitors” was chosen as it satisfied the requirements we 
put forth in designing this docking experiment (103).  
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In this paper, five peptide-based compounds were synthesized, 1a – 1e [Figure 
31].  These compounds were drawn and energetically minimized in Spartan at the 
B3LYP / 6-31+G* level, and then imported into Molegro where they were docked within 
the active site of a di-metalated (Co(II)) MetAP according to the procedure in Section 
3.1.3.2.  The PDB file 1CS3 was used for this experiment as the assumption by the 
authors was that the two metal ions were required for inhibitory action based on the 
chelating nature of the chemical agents designed.  Therefore, it was our feeling that for 
true faithfulness to the lab bench and experimental reality, it was important to keep the 
authors assumptions with the in silico model being designed in Molegro.  However, as a 
control, we also tested these same inhibitors on a mono-metalated species of MetAP 
with Mn(II) in the active site [PDB Code: 2GTX], to assess whether these virtual 
inhibitors could differentiate between the virtual active sites with different metal ions 
presented in MetAP’s catalytic centre.  The incorporation of metal ions in to the active 
site calculations adds another level of complexity to docking calculations since 
electrostatic charge and metal ion sterics need be taken into consideration.  Molegro 
takes into account these aspects of molecular interactions in three ways.  The van der 
Waals radii (VdW) is used, as well as the covalent radii between atoms of the protein 
substrate, ligands, and the metals themselves.  The specific radii for the metals we 
docked, Mn(II) had a VdW radii of 1.7 Å, while the covalent radii is 1.35 Å.  Molegro also 
assigns a charge to metal ions, +2 in the case of divalent metals that would be found in 
MetAP’s active site.  These factors, along with the fact that two Co(II) metals were 
present in 1CS3 while only one Mn(II) ion was present in the 2GTX PDB file, were 




Figure 31. Peptidyl hydroxamic acid inhibitors used in Hu and co-workers’ 
paper adapted for use in our molecular docking studies 
<Adapted from reference (103)> 
 
3.2.1.2. Results and Discussion 
 







Compound IC50 (uM) Mn (II) Co (II) 
1a 170 +/- 16 -72.437 -64.954 
1b 2.5 +/- 1.0 -137.382 -123.461 
1c 59 +/- 6 -114.342 -119.549 
1d 48 +/- 10 -112.129 -113.475 
1e 8.8 +/- 2.7 -119.193 -120.057 
Table 4. Comparison of Hu et al.’s compounds’ IC50 values and their Molegro 
scores with different metal ions. 
 
Two patterns become clear after viewing Table 4.:1) In this instance, Molegro 
appears reasonably predictive in ordering of the compounds that have IC50 values far 
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apart; 2) Molegro is not totally reliable when comparing compounds that have IC50 
values fairly close to one another.   
 
In analyzing the calculations for compounds 1a-c, it appears that if they are 
ranked in order of IC50, the order is 1b < 1c < 1a.  This is also the result if the 
compounds are arranged by either Molegro score provided in Table 4.  Therefore, with 
the previous assumption in mind, that a lower Molegro score (more negative) is 
correlated to a tighter binding, one can see that with IC50’s reasonably far apart, ie. 170 
uM versus 2.5 uM, it is possible to have confidence in the suggestion that Molegro can 
be capable of predicting lead candidate compounds.   
 
In the case of IC50s that are quantitatively similar, as in the case of compounds 
1c and 1d, despite 1d having a lower IC50 value, its Molegro scores were greater in both 
Mn(II)- and Co(II)-metalated enzymes, implying that the inhibitory potential would be 
lesser, when in experimentally the opposite is the case.  This was expected.  It has 
been our experience within our laboratory that compounds at the upper and lower 
echelons of inhibitory potential are quickly discerned with virtual screening methods, 
whereas compounds that lie in the middle range (in this case, between 8.8 and 59 uM) 
are not separated with the same ease.   
 
There was not much of a difference in Molegro scoring for utilizing different 3D 
protein structures with different metals in the active site.  In spite of subtle differences in 
actual energetic scores, most probably due to the changes of orientation in the active 
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site between the di-metalated Co(II) and mono-metalated Mn(II) forms (27), the 
differences did not impact the ranking as previously described, both in the cases of IC50 
values and molecular docking rankings.  
 
Ultimately, we were satisfactorily assured that after performing this comparison of  
Molegro’s results with that of peer-reviewed literature, our experience would not be a 
computerized simulation that did not at all represent what actually happens in the 
process of ‘wet science’.  Rather, we obtained initial evidence that as a tool for 
screening strong candidates for therapeutic usage out of a larger group, Molegro, and 
its MolDock scoring function, could be of use as a preliminary evaluatory technique 
given the caveats just mentioned. 
3.2.2. Experiment #2:  Comparing the Spatial Orientation of Ligands Bound 
Within the Active Site of a 3D Protein Structure With Docked Ligands in 
Molegro     
 
 Next, it was important to evaluate whether the docking performed by Molegro 
would yield docked structures similar to the 3D structures deposited in the Protein 
Databank.  Previous literature findings (104), along with experience in our laboratory, 
has shown that on occasion, the docked structure is almost completely opposite in 
orientation to the original ligand-bound 3D structure, something that will be elaborated 
upon later on this in this Chapter.  However, at that time, it was absolutely necessary to 
be sure that the docked structures obtained and the resultant energies acquired through 
MolDock scoring were legitimate and realistic, especially when compared to the 
published structures and their own energetics.  Otherwise, the docking scores could 
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potentially be irrelevant if the docking conformation does not relate to what actually 
happens during crystallography and inhibition in solution.   
 
3.2.2.1. Experimental 
A structure obtained in our lab in conjunction with Matthews and Lowther at the 
University of Oregon was used (PDB code: 1CS3), namely of eMetAP bound to 
difluoromethionine (DFM).  This was then compared to a Spartan-built duplicate of the 
difluoromethionine docked to the same PDB file, albeit without the original probe 
present.  Docking was performed as in Section 3.1.3.2., first with the original DFM 
ligand that is included in the original PDB file, and then with the Spartan-made version. 
 
 
3.2.2.2. Results and Discussion 
  
 Initially, no structure obtained through docking matched the ligand-eMetAP 
conformation in the original PDB file.  Therefore, a modified version of the docking 
procedure had to be employed.  Molegro has a feature that allows the user to add in 
constraints, user-specified parameters that influence the behaviour of the ligand docking 
within the active site of 3D structure, to the work space.  In this case, the constraint to 
be considered was distance, specifically between particular atoms within the work 
space.  Based on the mechanism of MetAP, it was essential to account for the metal ion 
within the active site, as its coordination to the substrate during catalysis is paramount 
in the chemical mechanism of the enzyme.  In the case of the PDB file ICS3 structure, 
Co(II) is present as the metal ion.  Although two Co2+ ions are found in the ICS3 
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structure, neither appeared proximal to the carboxyl oxygen atoms of the inhibitor in 
these docked poses, a structure that would be expected based on the mechanism of the 
enzyme.  Therefore, a distance constraint was added that dictated the carboxyl of DFM 
could be no greater than 2.8 Å away from one of the metal ions (the precise details to 
be discussed in a later section), which is within the limits seen in the 3D structures of 
most 3D MetAP structures deposited thus far.  Once this was done, docking was 
performed as before, and a more realistic portrayal of the in silico built DFM ligand was 
seen docked with MetAP, as compared to the original 3D structure with DFM as the 
ligand [Figure 32].  As can be seen from the panels in Figure 32, the location of DFM, 
both the original and that prepared with Spartan, are almost identical.  The actual  
 
Figure 32. The active site of MetAP containing DFM in A) Original PDB File with DFM 
ligand; B) Spartan-made DFM docked with MetAP (PDB code: 1CS3) 
 
difference in distance between the two is approximately 0.15 Å in rms value based on 
Molegro’s RMSD matrix feature, which calculates differences in distance between 
ligands bound to a substrate.  As well, it can be seen when viewing Figure 32, that in 
spite of ligand flexibility, both the original DFM and the DFM created with Spartan 
exhibit almost identical conformations.  This is further corroborated by the scores 
obtained with the MolDock scoring function.  The original DFM ligand was scored at -
90.15 +/- 2.19 kcal/mol for the LEP, while the Spartan-made version’s LEP was scored 
at -88.93 +/- 1.96 kcal/mol.  Therefore, with the addition of constraints accounted for, 
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Molegro is reliable in terms of docking ligands in the same position and conformation to 
a protein of which a 3D structure is available.     
3.2.3. Experiment #3:  Predicting Biochemical Literature Findings with 
Molegro  
 
 The final test of Molegro came in the form of examining whether Molegro was 
capable of corroborating the findings of previously published work with respect to 
specific biochemical features of enzyme structure.  In theory, modifying the structure of 
the active site would have effects upon the ability of molecules to bind.  Though Molegro 
is only capable of docking ligands based on the information the user provides, we felt 
that the results should also be able to sufficiently support biochemical findings rooted in 
active site structure, as MolDock scoring is partially based on the electrostatic 
interactions and concomitant energetics of the macromolecular protein involved.  As 
well, Molegro possesses a unique feature allowing the user to mutate residues 
anywhere in the protein, and determining whether those mutations alter the energy of a 
ligand-protein interaction.  Therefore, it was of interest to investigate whether mutating 
key residues in the active site known to be integral to MetAP catalysis had any effect on 
the binding energy of a ligand within the active site of MetAP. 
   
3.2.3.1. Experimental 
 The substrate 4-nitrophenyl phosphate (4NP), a classically used substrate with 
alkaline phosphatases since the 1940’s and underscored by the work of Attias in the the 
1970’s (105, 106), was selected not only to investigate whether it, having been studied 
with so many enzymes before, would in fact be capable of binding to MetAP in silico, 
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but also whether it could act as a substrate or inhibitor of MAP (see Chapter 2).  
Therefore, 4NP was drawn and minimzed at the B3LYP / 6-31+G* level in Spartan and 
the resulting structure was imported in to Molegro [Figure 33].  Next, a mutation was 
made within Molegro at residue His 79 of MetAP, believed to be an important residue in 
the MetAP’s active site during NME (6, 19).  Specifically, the mutation changed the 
histidine residue to a glycine.  Docking was then performed as described previously in 
Section 3.1.3.2., with the only modification to the standard procedure being the constant 
for distance was added based on the observation that it was critical in order to obtain a 
realistic ‘pose’ (the conformation of a lead candidate) in the active site.   
                                    
Figure 33.  The electrostatic potential of 4-nitrophenyl phosphate (4NP) mapped on to the 
electron density at the B3LYP / 6-31+G* level in MacSpartan 8.0. 
 
3.2.3.2. Results and Discussion 
 Upon examing the results, it was found that the WT MetAP bound to 4NP in silico 
exhibited an energy of -115.7 +/- 4.218 kcal/mol for the LEP (again, presumably the 
tightest binding).  In the MetAPH79G mutant, the energy was -61.950 +/- kcal/mol.  
Clearly, such a drastic change in His79 rendered the 4NP ligand almost 50% less able 
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to bind to MetAP’s active site in this computer simulation.  This is most likely due to a 
loss of important electrostatic interactions in the active site of MetAP with the ligand.  
These interactions, as mentioned earlier, are believed to be important for orienting the 
substrate properly during catalysis, and though this evidence does not prove the 
importance of His79, it nicely mirrors the findings in the literature, and further 
demonstrates the reliability of Molegro as a virtual screening tool.  
 
 Evidently, based on these lines of inquiry, our examination of the Molegro 
docking software demonstrated some of its important capabilities (and limitations!) to 
explore ligand-protein binding interactions and provided a fairly accurate qualitative 
assessment of compound binding within the active site of MetAP.  Therefore, we felt it 
was possible to proceed further with a certain level of confidence to continue using 
Molegro to dock compounds used in actual biochemical assays and assess their ability 
to bind to the active site of MetAP.  
 
3.3. Sulfur- and Phosphorus-Based Probes of MetAP Revisited In 
Silico 
 As seen in Chapter 2, various phosphorus- and sulfur- containing molecules 
were used to assess their inhibitory activity against MetAP using the fluorogenic Met-
AMC assay, as had been previously described (69).  It was of interest to us to assess 
whether in fact these probes behaved similarly in silico as they did in vitro, as some of 
the previous experiments in this chapter have attempted to ascertain in a broad sense.    
Similiarly as before, we were particularly interested in the relationship sulfur-containing 
chemical moieties possess with the active site of MetAP, like the natural methionine 
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substrates, as well as the phosphonate behaviour as a tetrahedral intermediate during 
catalysis (46), hence the selection of these compounds.  Not only do the results give 
insight into the active site of MetAP during catalytic functioning, but they also provide 
some possible information into the mechanism of MetAP, and what drives enzymatic 
activity during NME.  Finally, because of the use of two differentially metalated active 
sites in the docking simulations, it was interesting to inspect whether the type of metal, 
and the number of ions present, had any effect on the ability of the compounds to bind 
to the active site of eMetAP.  It is quite apparent in the literature that compounds may 
exhibit specificity to a particular metalated form of the enzyme, such as the Fe2+-
metalated form of MAP (25).  This was especially appealing to us because of our belief 
that contrary to previous reports, MetAP is based on a mono-metalated mechanism, not 
a di-metaled one, in spite of these metalloproteases’ catalytic centres being often 
referred to as the “di-metal center” (6, 19).  
3.3.1. Experimental 
 All ligands were built in MacSpartan, minimized using a B3YLP / 6-31+G*  level 
set of calculations and then the three dimensional structures imported into Molegro 
[Figure 34 and Figure 35]. In addition, the PDB files 2GTX (containing a single Mn(II)) or 
1CS3 (containing two Co(II)) were also brought into Molegro to serve as the protein 
used in the docking experiments.  Docking was performed as per the procedure 
specified in Section 3.1.3.2. but the number of maximum iterations was input to be 100, 
rather than 25.  Docking calculations were then begun, and took approximately four 
hours per run.   
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3.3.2. Results and Discussion 
 
It is interesting to see when viewing Tables 5 and 6 that the more complex and 
large a molecule is, the lower the energy is and thus, a presumably stronger binding 
affinity is predicted to exist between the compound and active site of MetAP [Figures 33 
and 34].  This is probably due to the fact that the larger the compound, the greater 
number of interactions are present between the protein and the compound, in the form 
of hydrogen bonding, van der Waals interactions, hydrophobic interactions and ionic 
bonding.  The phosphate compounds serve as a case in point, where both the Co(II) 
form and the Mn(II) form of the enzyme exhibit the greatest binding affinity with BNPP 
and 4NP.  This is well correlated with the findings of Chapter 2 in Section 2.3.2.2., 
where the extremely low kinetic speed of catalysis of MetAP upon both these 
compounds was seen.  When taken with the findings of these docking experiments, 
perhaps the reason for their unique behaviour was that their high binding affinity 
contributes to the low turnover of the enzyme and therefore, lower kcat and Vmax values.  
In addition, the enzyme will contribute transition state stabilization when acting upon the 
normal substrate, and MetAP may not contribute optimal transition state stabilization to 








Compounds  LEP (kcal/mol) 
Bis(4-Nitrophenyl)Phosphate -115.7350 
4-Nitrophenyl Phosphate -89.4953 
Triethyl Phosphonoacetate -85.9436 
Iminobis(methylphosphonic) Acid -85.9206 
p-Nitrobenzenesulfonic Acid -80.3912 
Methyl-p-toluene sulfonate -73.6429 
Methylene Diphosphonic Acid -73.5820 
Pentane Sulfonic Acid -72.2908 
Norleucine Aminophophonate 
Diethyl Ester -68.5079 
(Aminomethyl)-phosphonic Acid -56.5613 
Aminomethane Sulfonic Acid -55.3685 
Methylphosphonic Acid -45.7636 
Table 5. LEP of phosphorus- and sulfur-based compounds docked with Molegro 
using PDB file 2GTX containing a single Mn(II) ion.  The phosphonate and sulfonate 











Compounds  LEP (kcal/mol) 
Bis(4-Nitrophenyl)Phosphate -120.903 
4-Nitrophenyl Phosphate -98.084 
Triethyl Phosphonoacetate -92.397 
Iminobis(methylphosphonic) Acid -91.588 
p-nitrobenzenesulfonic acid -79.326 
Methyl-p-toluene sulfonate -68.959 
Methylene Diphosphonic Acid -66.166 
Pentane Sulfonic Acid -64.546 
Norleucine Aminophosphonate 
Diethyl Ester -63.423 
(Aminomethyl)-phosphonic Acid -52.998 
Aminomethane Sulfonic Acid -51.774 
Methylphosphonic Acid -39.901 
Table  6. LEP of phosphorus- and sulfur-based compounds docked with Molegro 
using PDB file 1CS3 containing two Co(II) ions.  The phosphonate and sulfonate groups 
were protonated during docking. 
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Figure 34. Line drawings of compounds from Chapter 2 used for the molecular  
docking studies using Molegro.  
 
 
Figure 35. Compounds used in Chapter 2, mapped on to the electron density at the 
B3LYP / 6-31+G* level in MacSpartan 8.0. 
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 Both the sulfonates and phosphonates, as well as the phosphates, demonstrate 
binding affinities and it depends on other parts of the chemical structure to improve 
upon the interactions of these chemical moieties with the enzyme.  It also seems to be 
evident that as compounds become larger, LEP scores become lower.  For example, 
when one docks aminomethane sulfonic acid versus p-nitrobenzene sulfonic acid, lower 
energetic scores are recorded (again, potentially corresponding to what may be tighter 
binding).  This is interesting to deliberate because in general, MetAP kcat values 
increase as peptide size increases, inferring greater enzymatic turnover of substrate 
(78).  The tighter binding observed with the large substrate would typically correlate with 
a decreased ability to rapidly process substrate.  In the case of 4NP and BNPP, this 
may correlate with the fact that they, being phosphate diesters (RO-P(O2)-OR), might 
resemble the tetrahedral intermediate moreso and that is the reason for their highest 
ranking in terms of binding, both in silico, and as seen in Chapter 2, in vitro as well.   
 
3.3.3. Ionization States 
 The next step was to look into whether the ionization states of the phosphorus- 
and sulfur-based compounds affected binding [see Figure 36 for an example].  A priori, 
it was assumed that changing the ionization state would lower energetic scoring and 
therefore, result in greater binding affinity based on the enhancement of electrostatic 
interactions fostered by such a modification.  With this, it is important to take into 
account the pKa for the compounds we used.  The pKa of sulfonic acid is -2.6, the pKa 
of a phosphonate is 2.75 and the pKa of phosphates is 1.92 (the second pKa being 6.5), 
all indicating that deprotonation at physiological pH would be quite likely to occur.   
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 Ionization state changes were made either in Spartan, through removal of the 
hydrogen atom and applying a negative (or doubly negative) charge to the compound 
built, or in Molegro where one can manually change the charge and number of 
hydrogens present on an atom.  Docking was described in Section 3.1.3.2.  
 
3.3.3.2. Results and Discussion 
As can be seen in Tables 7 and 8, the differences in energy of the lowest pose 
between neutral molecules and those conferred with anionic or dianionic character is 
small.  To use the example given in Figure 36, with p-nitrobenzenesulfonic acid, the 
neutral species’ MolDock score is -73.642, while the negatively charged ion’s score is -
76.496, a 3-4% difference.   This is different than what was expected, where we had 
believed that differentially charged species would be exceptionally lower in energy (and 
tighter binding) than neutral molecules docked in the active site.  However, when 
bearing in mind the standard error between docking simulations is roughly 3% alone, it 
is apparently the case that ionization states alone do not play much of a role in 
determining the molecular docking binding affinities, and would not dramatically alter the 






Overall (-1) (LEP) 
Negatively 
Charged Species 
Overall (-2) (LEP) 
Bis(4-Nitrophenyl)Phosphate -118.342 -120.327 
4-Nitrophenyl Phosphate -100.993 -102.103 
Triethyl Phosphonoacetate -88.249 N/A 
Iminobis(methylphosphonic) Acid -87.104 -89.312 
p-nitrobenzenesulfonic acid -83.15 N/A 
Methyl-p-toluene sulfonate -77.643 N/A 
Methylene Diphosphonic Acid -75.328 -77.613 
Pentane Sulfonic Acid -74.117 N/A 
Norleucine Aminophosphonate 
Diethyl Ester -71.441 -74.001 
(Aminomethyl)-phosphonic Acid -59.322 -60.949 
Aminomethane Sulfonic Acid -57.316 -58.107 
Methylphosphonic Acid -47.978 N/A 
Table 7. LEP of phosphorus- and sulfur-based compounds docked with Molegro 
using PDB file 2GTX containing a single Mn(II) ion having different ionization states.  








Overall (-1) (LEP 
Negatively 
Charged Species 
Overall (-2) (LEP 
Bis(4-Nitrophenyl)Phosphate -122.144 -124.582 
4-Nitrophenyl Phosphate -92.315 -95.316 
Triethyl Phosphonoacetate -95.018 N/A 
Iminobis(methylphosphonic) Acid -94.235 -95.573 
p-nitrobenzenesulfonic acid -81.447 N/A 
Methyl-p-toluene sulfonate -71.288 N/A 
Methylene Diphosphonic Acid -68.519 -70.226 
Pentane Sulfonic Acid -66.384 N/A 
Norleucine Aminophosphonate 
Diethyl Ester -66.496 -67.941 
(Aminomethyl)-phosphonic Acid -55.782 -57.387 
Aminomethane Sulfonic Acid -54.697 N/A 
Methylphosphonic Acid -42.066 -43.899 
Table 8. LEP of phosphorus- and sulfur-based compounds docked with Molegro 
using PDB file 1CC3 containing two Co(II) ions having different ionization states.  
(N/A = not present in dianion form). 
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be in part supported by Molegro’s handling of charge interactions in general.  The 
MolDock score in Molegro typically treats charge interactions as ‘soft’, meaning the 
energetic penalty (or reward) is minor for electrostatic clashes and interactions.  This 
would easily explain the minute changes between the ionization states when ranking 
docked ligands. 
 
At this point, it is also important to note we decided that it was no longer 
important to continue to dock ligands in the active site of MetAP that would contain 
Co(II) ions, specifically in PDB file 1CS3.  This conclusion was based on the fact that 
the general trends observed to this point, like phosphate superiority in binding overall, 
remained the same when docking with either PDB file.  As well, there was not much of a 
change in numerical values when comparing the results between the Mn(II) active site 
docking and Co(II) active site docking.  These factors, combined with our ultimate belief 
that MetAP catalysis functions in a mono-metalated scheme, made us discontinue 
docking with the di-metalated Co(II) enzyme.  Therefore, from this point forward, 
docking was performed exclusively with the PDB file 2GTX.  
 
 
3.4. Addition of Constraints: Making In Silico Assays More Realistic 
 Based on the findings of the previous section which incorporated the native 
ionization states of the compounds docked with MetAP into the virtual screening 
process, it became further relevant to see whether adjusting other parameters, in an 
effort to further integrate more realism into molecular docking, would alter docking 
results.  As is the case in molecular docking and in silico chemistry in general, the 
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results provided by software like Molegro have to be interpreted with the knowledge that 
in spite of whatever one does in terms of modeling molecular phenomenon, nothing 
replaces wet lab work.  Therefore, in spite of the interesting results that have been 
obtained through the experiments performed thus far, in order to make the modeling as 
faithful to reality as possible, as well as to obtain an improved understanding on the real 
strength of Molegro’s modeling abilities, various parameters were modified to foster 
greater fidelity to the binding assays performed in Chapter 2.  Within the molecular work 
space, these parameters are introduced as “constraints”, which basically infers that one 
is creating limitations to confine specific elements of the search space MolDock works 
within when arriving at LEP of a docked ligand. 
 
 In addition, it was visibly noted that at times, similar to what was mentioned in 
Section 3.2.2., the LEP would be completely unrepresentative of what was actually 
occurring in the active site based on the protein X-ray structure.  In fact, for several of 
the phosphorus- and sulfur- containing molecules used in this work, the position of the 
molecule would almost be completely opposite in conformation to the ligand deposited 
with the protein in the 3D structure obtained from the Protein Data Bank, even when the 
ligands were quite similar (104).  Although this phenomena has been observed in other 
studies (104), it did not fit well with our intent in reproducing reality as best as possible 
within the confines of molecular modeling.  Therefore, after a range of modifications to 
the Molegro work space in the hopes of discovering what would eliminate this problem, 
the constraints described below were found to best correct this dilemma.    
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 The constraints used in our experiments with Molegro are also of interest as 
previous literature using Molegro has not utilized them in their virtual screening.  Nine 
papers, including the publication that introduced the MolDock scoring function by 
Thomsen and Christensen in 2006 (100) have so far used Molegro in their virtual 
docking studies to different ends.  However, none of the published articles went beyond 
the default settings when performing their in silico experiments.  It is was our belief prior 
to adding the constraints that though the “initial screen” (the term we dubbed to refer to 
the basic docking performed without the addition of constraints and modifications to the 
Molegro work space) provided useful and valuable information regarding compounds 
binding within the active site of MetAP, more information that was potentially more 
realistic, based on adding previously observed experimental data through constraints, 
would be functionally of greater value.  For example, relying on the ‘initial screen’ 
means that the user is also implying the active site of the enzyme is completely static, 
and no residue movement or larger, general structural motif mobility is observed.  This 
situation could be interpreted as implausible, as even the most amateur enzymologist 
knows of examples of conformational changes observed during most substrate binding 
events during enzyme catalysis.  Therefore, in order to evaluate whether our 
assumptions were true, it was necessary to further understand how constraints affected 
the Molegro docking progress, and how they function within the context of molecular 
modeling in general. 
 
 Each constraint was added, followed by the next constraint in the sequence 
described below such that once a constraint was added, the results were kept and the 
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subsequent constraint was put in to the Molegro work space.  This means that following 
the first instance below of constraint implementation, subsequent results are a sum of 
total constraints in use within the Molegro work space during virtual docking 
experiments. 
 
3.4.1. Distance Constraints  
 As mentioned earlier, when docking certain ligands into MetAP’s active site, the 
LEP, which would seemingly represent the conformation most tightly bound to the active 
site, visibly appeared to be almost diametrically opposite in conformation to that 
observed in the deposited structure.  An example of this can be seen in Figure 37, 
where in contrast to Panel A, Panel B shows the Spartan-built aminomethyl phosphonic  
 
Figure 37. The active site of MetAP [PDB code: 2GTX] with Mn(II) ion (Grey, in Space-fill 
for emphasis) with A) Included Norleucine ligand; b) Spartan-made 
Aminomethylphosphonic acid ligand docked using Molegro (initial scan). 
 
acid oriented a way that does not conform to what should be observed.  The 
phosphonate group, for one, where a negative charge would be present and therefore 
attracted to the positive charge of Mn2+, appears to be directed away from this area and 
instead, the methyl group is proximal to the Mn(II), which would not be the case based 
on the general rules of inorganic chemistry.  One pose in each of the multiple runs was 
found by MolDock that did more closely bear resemblance to the norleucine ligand’s 
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docked position.  However, they were different in terms of docked location by an 
average rms value of approximately 10 Å (found using the RMSD Matrix feature in 
Molegro), and their LEPs were between 15 to 20 percent higher, indicating weaker 
binding.  Therefore, the software has found a pose of best fit topologically, without 
taking into account reality, where in spite of MolDock being considered the best scoring 
function currently available (100), it apparently has mistaken various interactions to 
occur when in fact they would not. 
 
One of the constraints that can be added to the Molegro workspace is the 
“distance constraint”.  As alluded to earlier, the distance constraint functions to limit the 
ability of a specific atom to deviate a specific distance away from another atom the user 
prescribes.  For example, if it was previously determined that a specific group on a 
ligand remains close to a certain residue of an active site, then one can choose that 
group on the ligand, and specify the maximum distance allowed it to be oriented away 
from a specific atom on the residue in question.  In this case, it would be relevant with 
regard to His79 or His178, both known to be proximal to the Met group of newly 
synthesized peptides for their roles in nucleophilic attack and coordination, respectively 
(19).   
 
3.4.1.1. Experimental 
In our experiments, a distance constraint was created such that sulfate and 
phosphonate, or phosphate groups in the case of 4NP and BNPP, would not be allowed 
to be more than 2.8 Å away from the Mn(II) metal ions present in the active site.  This 
limitation was based on literature precedents (26, 107), as well as the actual distance 
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measured in the original PDB files between similar groups on the ligands deposited and 
the metal ions present.  We were also interested in whether there would be a significant 
change in energy scores of the ligands as a result of implementing this constraint.  
Docking was then performed as in the procedure set forth in Section 3.1.3.2. 
 
3.4.1.2. Results and Discussion 
From Table 9, it can be seen that except for the phosphate compounds 4NP and 
BNPP, the distance constraint did not change very much energetically for the 
compounds used in this work, except BNPP which was drastically reduced.  This 
outlying result is probably based on the massive size of BNPP and its ability to no 
longer be docked in any position possible with the introduction of this constraint.  In 
terms of binding strength order, the only compounds that changed positions were p-
nitrobenzenesulfonic acid and methyl-p-toluene sulfonate, albeit, the difference between 
them in LEP was marginal.  However, the actual appearance of the docked ligand (in  
Compounds  LEP (kcal/mol) 
Bis(4-Nitrophenyl)Phosphate  -99.532 
4-Nitrophenyl Phosphate -76.966 
Triethyl Phosphonoacetate -73.911 
Iminobis(methylphosphonic) Acid -73.892 
Methyl-p-toluene sulfonate -71.156 
p-nitrobenzenesulfonic acid -67.959 
Methylene Diphosphonic Acid -66.169 
Pentane Sulfonic Acid -63.785 
Norleucine Aminophosphonate 
Diethyl Ester -60.287 
(Aminomethyl)-phosphonic Acid -53.733 
Aminomethane Sulfonic Acid -52.601 
Methylphosphonic Acid -43.475 
Table 9. LEP of phosphorus- and sulfur-based compounds docked with Molegro 
using PDB file 2GTX containing a single Mn(II) ion after application of a distance 
constraint centered around the Mn(II) metal ion. 
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the form of the lowest energy pose) became much more realistic, and closely resembled 
the original ligand provided in the deposited 3D structures.  This was observed in all 
compounds docked, where functional groups such as the phosphonate or sulfonate 
group were appropriately positioned relative to the metal ion, and the alkyl groups (if 
present) arranged expectedly from sources of electrostatic charge [Figure 38].  For one, 
it would be an unfortunate situation if the energies within the newly constrained 
simulations had dramatically changed, as it would then be hard to believe that Molegro  
 
 Figure 38. A demonstration of the active site of MetAP in Molegro with a distance 
constraint applied to the Mn(II) metal ion (constraint is represented by the green spheres 
surrounding it) insuring proximity to the sulfonic acid group of methylsulfonic acid 
 
can recognize differences in compound functionality in a broad sense, and not assert 
that one, with molecular modeling and this form of in silico medicinal chemistry, is 
forcing results that are not at all in line with what occurs in reality.  It was also intriguing 
to see that the energies for both 4NP and BNPP, the novel MetAP substrates and 
inhibitors, were so different with the newly imposed constraint considering their unique 
behaviour during Chapter 2’s assay experiments.  This perhaps implies that the new 
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constraint imposed upon these compounds, in spite of their still lowest binding energy, 
may not have been appropriate given that they do not seem to behave as the other Met-
AMC substrate typically did in the kinetic assays.   Most importantly, however, it is 
reassuring to see that in spite of this manually applied parameter, the results for the 
compounds used to study the functionality of specific groups in the active site of MetAP 
were not significantly affected by this seemingly large modification to the docking work 
space, such that the general trends observed in the results provided by Molegro could 
be rationally considered. 
 
3.4.2. Active Site Waters 
 
 Based on the positive results supplied by adding the distance constraint for metal 
ions, we decided that the next step would be to incorporate the active site waters into 
the modeling of MetAP’s active site and the docking of ligands within it.  As mentioned 
previously, active site waters are typically left out of docking experiments, however, as 
the mechanism we have put forth demonstrates, as well as previous literature has 
established (6, 19), waters within the active site of MetAP play an integral role in NME 
hydrolysis of immature peptide substrates.  Therefore, it was important to include them 
to confirm our mechanism, as well as further applying realistic phenomena to our 
computational modeling experiments.   
 
3.4.2.1. Experimental 
 Initially, the PDB file 2GTX was imported into Molegro, but in contrast to previous 
docking experiments (as specified in Section 3.1.3.2.), all waters were included (268 
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waters exist in the dimeric form of this 2GTX structure of MetAP).  The active site area 
was expanded, and the cavity in this region was automatically detected in Molegro.  
Then, with the cavity selected, waters were searched for in this region that would be 
proximal to compounds in this area, and would therefore be theoretically involved in 
catalysis.  Two waters, 890 and 902 [Figure 39], were selected based on their presence  
 
Figure 39. Two active site waters (890 and 902 in PDB code: 2GTX) (large red spheres – 
space filled versions of water molecules in Molegro) proximally located to the 
phosphonate group of BNPP 
 
in the cavity-highlighted active site, their proximity to relevant residues (ie. His79), and 
their proximity to the included inhibitor.  The file was then closed, and re-imported into 
Molegro, however, this time, only waters 890 and 902 were selected and imported into 
the Molegro work space.  Docking was then performed as normal as per Section 
3.1.3.2.  However, when waters are contained in the Molegro work space, prior to 
performing the docking process, the program asks you whether to include them as a 
constraint, and to be treated as such.  Similarly to the distance constraint imposed with 
the metal ions, Molegro treats the waters in kind, and bases its calculations of the 
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lowest energy poses with water molecules in the search space proximally to specified 
atoms of the compounds to be docked.   
 
4.4.2.2. Results and Discussion 
From viewing Table 10, one observes that there is quite a significant effect upon 
the LEPs from adding the waters to the active site of MetAP.  As can be seen, there is 
an average increase in energy of best pose of 8-11% in kcal/mol per compound on 
average when the docking simulations are run with waters 890 and 902 included in the 
Molegro work space and treated as constraints.  This increase in energy, and 
consequent assumed decrease in binding affinity of the compounds for MetAP’s active  
 
Compounds  LEP (kcal/mol) 
Bis(4-Nitrophenyl)Phosphate -88.204 
4-Nitrophenyl Phosphate -68.348 
Iminobis(methylphosphonic) Acid -67.476 
Triethyl Phosphonoacetate -66.458 
Methyl-p-toluene sulfonate -65.741 
p-nitrobenzenesulfonic acid -63.697 
Methylene Diphosphonic Acid -60.993 
Pentane Sulfonic Acid -58.723 
Norleucine Aminophosphonate 
Diethyl Ester -56.393 
(Aminomethyl)-phosphonic Acid -50.014 
Aminomethane Sulfonic Acid -48.918 
Methylphosphonic Acid -40.084 
Table 10. LEP of phosphorus- and sulfur-based compounds docked with Molegro 
using PDB file 2GTX containing a single Mn(II) ion after active site waters included and 
treated as constraints. 
 
site are most likely due to energetic penalties incurred by the compounds since they 
were required to be proximal to the water molecules, thereby losing other binding 
fostering interactions.  Interestingly, this is in spite of the creation of hydrogen bonds 
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with the water molecules not previously found, generally since the compounds under 
study possess multiple oxygens with hydrogen bonding capability.  One is actually 
capable of viewing these hydrogen bonds with a special feature of Molegro which allows 
the user to specifically view potential hydrogen bonds, which appear as broken green 
lines between donor and acceptor atoms [Figure 40].  This result is counterintuitive 
initially, but since the trends generally remain the same, with only minute changes in 
position with marginal energy differences by aminomethylphosphonic acid and 
aminomethane sulfonic acid, as well as iminobis(methylphosphonic) acid and triethyl 
phosphonoacetate, these results do offer insight into treatment of waters in the active 
site of MetAP as well as the general role of waters in the catalytic area of an enzyme. 
 
Figure 40. Active site waters (In red, space-fill for emphasis) in MetAP’s active site with 
hydrogen bonds exhibited using green broken lines 
 
4.4.3. Side Chain Flexibility 
 Another constraint available to the user in Molegro when docking ligands on a 
macromolecular complex, and the last one we felt relevant to these studies, is called 
“side chain flexibility”.  As one may guess, this refers to the idea that amino acid residue 
side chains are flexible, not rigid, and during catalysis, different portions of the residue 
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may occupy different points in space at any given time.  This concept is certainly not 
novel, as most biochemical machinery has been noted to be in flux during activity (108), 
not the least enzymatic catalysis!  Yet, many previous modeling publications have not 
included this concept in their virtual screens, nor have any of the articles that 
incorporate Molegro into their research published as of yet (108).  Though, at the same 
time, various studies have mentioned that it is part of the reason virtual screening 
methods have continued to elicit false positive hits for lead candidates, as high as 
33.3% (95).  Therefore, as previously said, this would be the first study to date which 
actually utilizes the software’s capabilities in incorporating phenomena other than 
structural biochemistry into in silico docking models.  Certainly, in contrast to the 
previous two constraints, this is undoubtedly the most complex constraint and needs to 
be treated carefully.  It is of course computationally demanding as many different 
arrangements need to be tested for docking interactions. 
  
 It can be difficult to state with conviction whether the movement of one area of a 
macromolecular complex will or will not affect the movement and structural 
conformation of another area of the larger assembly.  It has definitely been previously 
noted in other enzymes, such as the classic example of triosephosphate isomerase, 
where movement in the sixth conserved loop of this glycolytic enzyme affects other 
neighbouring regions (109).  Therefore, the original fear in using this constraint was that 
modification in one area should in theory affect other areas, and so therefore, one could 
not incorporate flexibility in one region without doing so in another.  However, thankfully, 
in the case of MetAP, most structural movement has been previously identified in the 
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literature, and so therefore, we felt that if we incorporated the findings of major structural 
changes during catalysis, it was: a) better than maintaining rigidity, which would 
definitely not occur during actual ligand binding; and b) would still follow previous 
literature conclusions and therefore be faithful to what has been previously observed.     
 
 
4.4.3.1. Experimental  
Docking was performed as previously described in Section 3.1.3.2.  However, the 
option for side chain flexibility was selected, and set up.  Residues known to be involved 
in movement during catalysis were selected based on previous literature findings.  
Specifically, residues Tyr62, His63, Gly64, and Tyr65 (these four comprising what is 
known as “the YHGY loop”), His79, Asp97, Asp108, His178, and Trp221, all noted 
previously as being significantly mobile during ligand binding at the time of catalysis (6, 
19, 21, 110), were selected as flexible side chains, with the individual settings left at 
default.  The default setting meant that each side chain was to be rotated through the 
Molegro-assigned torsional degrees of freedom, unique for each amino acid, to find the 
most optimal torsional angles from which to assign bond energies and the overall 
energies of each LEP.  More specifically, a histidine residue (we assigned side chain 
flexibility to three histidine residues in MetAP’s active site) is given two degrees of 
freedom, meaning Molegro uses three specific side chain conformations for histidine in 
arriving at a torsional bond angle to be used in arriving at EIntra based on the unique 
hybridization of the bonds in each conformation.  For aspartate and tryptophan, two 
degrees of freedom are alloted, three for tyrosine, and only one for glycine.  Once side 
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chain flexibility was set up, the selected residues’ side chains become surrounded by a 
spherical net of varying blues and purples, depending on the settings selected, in the 
work space, denoting the region of potential movement possible with this setting 




Figure 41. Side chain flexibility represented in the Molegro work space with MetAP active 







3.4.3.2. Results and Discussion 
Of all the constraints added, side chain flexibility elicited the greatest difference in 






Compounds  LEP (kcal/mol) 
Bis(4-Nitrophenyl)Phosphate -74.327 
4-Nitrophenyl Phosphate -61.496 
Triethyl Phosphonoacetate -58.358 
Iminobis(methylphosphonic) Acid -60.428 
Methyl-p-toluene sulfonate -57.579 
p-nitrobenzenesulfonic acid -55.639 
Methylene Diphosphonic Acid -52.914 
Pentane Sulfonic Acid -53.436 
Norleucine Aminophosphonate 
Diethyl Ester -49.853 
Aminomethane Sulfonic Acid -48.372 
(Aminomethyl)-phosphonic Acid -47.852 
Methylphosphonic Acid -37.876 
Table 11. LEP of phosphorus- and sulfur-based compounds docked with Molegro 
using PDB file 2GTX containing a single Mn(II) ion after the implementation of side chain 
flexibility. 
 
‘initial scan’, from Section 3.3., and with the same basic settings of those studies 
utilizing Molegro from other research groups (96, 99, 102, 111, 112), BNPP had an 
energy of best pose of -117.9 +/- -4.215.  Following the addition of distance constraints 
to the metal ion and active site waters, the calculated value became -88.204 +/- 3.996.  
However, with the addition of the side chain flexibility constraint following the previous 
constraint integration, the lowest energy pose score changes drastically to -74.33 +/- 
2.473.  This dramatic change is observed in all compounds docked with MetAP under 
this constraint. Nevertheless, the general trend in binding potency remained the same.  
There was only a single change in binding order between aminomethylsulfonic acid and 
aminomethylphosphonic acid, which does not change the picture much as they were 
already among the weakest binding compounds.  With this, the LEP scores increased, 
effectively meaning that binding energy decreased as a result of this addition of this 
constraint.   
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Such a large adjustment in LEP scoring because of implementing side chain 
flexibility is interesting because of its positive direction. This is not entirely unexpected 
however.  It is fitting that changing the relative mobility of residue side chains intimately 
involved in active site interactions with ligands taken up by the enzyme should have a 
considerable impact upon the energetics, and therefore the binding, of the ligand-
enzyme complex.  In an active site where the residue side chains remained static in 
position, it would be possible for the ligand, based on Molegro’s iterating ever more 
favourable poses, to find a position where it remains flexed into a position that would be 
bound more tightly than if residues in this region were to become mobile themselves.  
Residue movement itself may, and the consequent steric obstructions this would 
introduce into the cavity region, disable movement of the ligand into simply any position 
that would satisfy the requirements for tightest binding possible.  The legitimacy of this 
finding itself is substantiated by one of the preliminary experiments done earlier, in 
Section 3.2.3., which found residue mutations in the literature (His79, in this particular 
experiment) which affect enzymatic activity also influence the in silico binding ability of 
ligands to the active site.  Though there were no mutations resulting in the decreased 
observed binding of the compounds, it is probably the case in this instance that the 
newly mobile residues selected, based on their participation in catalysis, render the 
simulation more realistic energetically speaking.  Even still, though the scores changed, 
the trend has generally remained the same in terms of binding order, so this ‘reality 
shift’ induced by side chain flexibility may be just that – a shift to more realistic binding 
energies.    
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3.5. Correlation of Binding Assay Findings with Virtual Docking 
Results 
The final test of molecular modeling reliability with respect to the virtual docking 
experiments performed in this chapter is through showing a definitive relationship 
between real biochemical assays that use the actual compounds and enzymes 
discussed rather than computer-simulated versions.  So far, three of the nine papers 
that have performed virtual screening experiments with Molegro have done so in an 
effort to coordinate biochemical binding assays with the concordant results of Molegro.  
For instance, earlier this year (2009), Khan and colleagues at the University of Tromso, 
Norway, reported the discovery of novel thermolysin inhibitors from an NCI compound 
library of 273,000 molecules through Molegro, and correlated the biochemical binding 
affinities of the lead candidates with their in silico models (96).  Their findings suggested 
that overall, Molegro possesses value as a tool to be used in what they called “virtual 
high throughput screening” (vHTS), and was reliable enough to use as a way to find 
lead candidates from a large, virtual compound library against a target (thermolysin) that 
had never been tested against inhibitors of the kind found in that library (3-
nitrobenzamide compounds) (96).  Moreover, they were able to correlate their binding 
assay results with the lead candidate compounds with those done in silico, with a fairly 
high confidence level (96).  Based on the findings of this group, we decided to perform 
the same type of correlation with our phosphorus- and sulfur-based compounds and 
E. coli methionine aminopeptidase.  Moreover, we decided to perform this correlation 
between the initial scan virtual docking results, and the results that had been acquired 
after applying the various constraints.  In this way, it would give insight into whether the 
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addition of constraints improved docking accuracy relative to what was observed at the 
lab bench, or decrease it. 
 
3.5.1. Experimental 
 The docking results (in the form of LEPs) from this chapter without any 
constraints (the initial scan), and all constraints added, as well as the IC50 values from 
Chapter 2 of the phosphorus- and sulfur-based compounds were imported into 
Microsoft Excel, where scatter plots were created using both sets of values and R2 
values obtained. 
 
3.5.2. Results and Discussion 
As can be seen from Figures 42 and 43, as well as taking into account the R2 
values of both sets of IC50-LEP relationships, there is a positive correlation between the 
results of the virtual docking experiments and those of the actual experimental binding 
assays.  Almost all of the 12 compounds assayed, except pentane sulfonic acid, and to 
some extent, 4NP, demonstrate a good correlation between their binding within Molegro 
and their actual IC50 values when performing the Met-AMC fluorogenic assays.  The 
lack of perfect correlation is expected, especially in light of the fact that virtual screening 
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Figure 42. A correlation of IC50’s of the phosphorus- and sulfur-based compounds under 
study with their MolDock LEP scores after the initial scan, R2 = 0.7726. 
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Figure 43. A correlation of IC50’s of the phosphorus- and sulfur-based compounds under 
study with their MolDock LEP scores after the addition of constraints including distance, 
active site waters and side chain flexibility, R2 = 0.7589.  
 
compounds assayed (96).  The correlations, both before and after constraint 
implementation, are 0.7726 and 0.7589, respectively.  The reason for the slight variation 
is probably because of the change in position of various compounds, namely 
triethylphosphonoacetate, p-toluenesulfonic acid, aminomethylphoshonic acid, and 
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aminomethane sulfonic acid, albeit, their energy differences were minor and thus, 
elicited only minor changes in R2.  The R2 values themselves are reasonable, their 
range supported by the previous literature on the subject, which show correlations of 
0.67 (Khan et al.), 0.68 (Fogel et al.) and 0.87 (Sivaprakasam et al.), with their specific 
values being statistically considered to represent positive correlation (96, 102, 111).  It 
is worth mentioning that even with the use of the various constraints, the correlation 
remains virtually unchanged.  Therefore, our initial inquiry into whether the accuracy of 
Molegro would improve with their use has shown that our initial scan, along with those 
groups previously demonstrating its use in the literature, may be sufficient in 
determining some lead candidates within a group of compounds.      
 
  3.6. Summary 
 In summary, we have shown through a series of controlled docking experiments, 
the strengths and weaknesses in the use of the virtual docking software program, 
Molegro, and its potential use ability in performing virtual screening of molecular 
candidates for inhibitor discovery.  Molegro appears to be a capable and reliable 
program to perform the molecular modeling of ligands docked on a macromolecular 
substrate (given the above described limitations!) , based on the program’s ability to not 
only computationally support literature findings, but also to potentially replicate quite 
faithfully, in some instances, in vitro ligand and substrate behaviour.  As well, we have 
demonstrated that although it is possible with Molegro to model phenomena in a fairly 
complex manner, moreso than has previously been done to date, it is also feasible to 
rely on the more simplified settings provided with Molegro by default to perform virtual 
 119 
scans of compounds and identify, with a reasonable level of certainty, lead candidates 
in the drug design process.  This is underscored by our correlation of our phosphorus- 
and sulfur-based compound binding assays with these molecular modeling results to a 
favourable degree of reliability, whether the constraints we applied were included in the 





































Chapter 4. Conclusions and Future Work 
 
 The objectives of this project were to explore the basis of MetAP catalytic 
functioning through probing its activity using various phosphorus- and sulfur-based 
probes, as well as novel fluorinated substrates.  We also demonstrated the merits of a 
predictive in silico approach to the identification of lead candidates  
in the pursuit of potent enzyme inhibitors.   
 
The ester phosphates, were most potent during our assaying of MetAP.  This 
was probably because of their resemblance to MetAP’s natural peptidic substrate’s 
tetrahedral intermediate they are believed to exhibit during binding, hence their 
relatively low IC50 values and their concordant molecular modeling scores when docking 
in the enzyme’s active site.  However, all molecules assayed appeared to exhibit 
binding affinities, and this was dependant on their differences in chemical structure and 
how this affected each compounds interactions with the active site of MetAP.  
Interestingly, substrates known to be processed rapidly by MetAP, when modified with 
fluorine, as in the case of DFM-AMC and TFM-AMC, were demonstrably less prone to 
be catalyzed than without fluorine additions.   
 
We also showed that MetAP may have a previously unknown function, being the 
removal of pNP from ester phosphate compounds not previously known to be 
catalytically acted upon by this enzyme.  Though it is becoming more widely accepted 
that enzymes may have more than one natural substrate, this is novel in the case of 
MetAP and deserves further attention.   
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 Further research is warranted in several areas.  It would be interesting to assess 
the inhibitory potency of not only phosphonates with greater functional group diversity, 
taking cues from the phosphates studied in the substitutions on the oxygen groups.  The 
low uM range observed in the ester phosphates we studied, and the more potent of the 
phosphonate group, could be enhanced potentially with functional group additions and 
general expansion in these areas.   
 
 More work is also worthy in examing fluorinated substrates like DFM-AMC and 
TFM-AMC.  We have demonstrated that these compounds are both processed less 
readily by MetAP than the chromogenic Met-AMC.  Though previous work in our 
laboratory has focused on this general area, little still remains in the field at large 
regarding unnatural amino acid substituted peptide substrate kinetics with other 
enzymes.  Their unique position to be probed by means like 19F NMR render them a 
valuable tool in biochemical studies, and it is hoped this will expand in the future. 
 
 Finally, we have developed a vHTS to be used in the drug design process, and 
showed that in spite of adding more realistic details to a virtual environment, the 
software’s ability to pick out lead candidates amongst a larger group of possible 
inihibitors remained the same.  The fact that compounds in the middle range were not 
so readily teased apart from one another, in addition to the previously observation and 
our own experience with the software docking ligands in inappropriate positions, means 
that work may need to be done in regards to refining the existing algorithms used in 
assessing active site interactions with potential therapeutics.  Though MolDock appears 
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to be a reasonable molecular docking program, work still needs to be done in further 
rendering it capable of being more realistic to ever be truly valuable as a drug discovery 
tool. It should be added that all other docking software programs suffer from this 
weakness and that Molegro is not different in this regard. 
  
 Ultimately, the work presented in this thesis attempts to explore preliminary 
studies on understanding and inhibiting eMetAP.  It is hard at times when performing 
experiments and analyzing results to keep in mind the bigger picture as the details 
under focus are so diminutive.  As well, the arduous nature of laboratory research often 
obscures clarity and seems insurmountable.  However, in spite of the toils of science, 
when the quest for knowledge to enrich all members of society is at hand, larger than 
each and every one involved, no detail is too minor to leave unrevealed, no sacrifice is 
too much to make, and no task is too difficult to perform when the rewards of these 
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